# BioThera Solutions Inc. — Full Content Corpus # llms-full.txt — full-text companion to /llms.txt (https://llmstxt.org) # # This file concatenates the visible text of BioThera’s core scientific # and product content so an AI engine can ingest the whole citable corpus # in one fetch. It is generated from the live site at build time. The # curated index, company facts, publications, and model-framing guidance # live in /llms.txt: https://biotherasolutions.com/llms.txt > Canadian biotechnology company building scalable, standardized extracellular > vesicle (EV / exosome) biomanufacturing infrastructure. Commercial entry point > is plant-derived EV dermocosmetics (the Vesera Serum); longer-term roadmap > covers regenerative medicine, drug delivery, and immuno-oncotherapeutic EVs. > Founder Frédéric St-Denis-Bissonnette, PhD is a named contributor to the > MISEV2023 international consensus guidelines for EV research. ============================================================================== # Technology — EV biomanufacturing platform Source: https://biotherasolutions.com/technology ============================================================================== BioThera Solutions — Technology # Full-Spectrum EV Platform. Precision Biomanufacturing from Source to Specification. BioThera Solutions operates a full-stack plant-derived extracellular vesicle (EV/exosome) biomanufacturing platform — from upstream botanical isolation to downstream MISEV2023-compliant characterization, designed for consistency, traceability, and scalability. Fundamentals ## What Are Extracellular Vesicles (EVs / Exosomes)? Extracellular vesicles (EVs/exosomes) are nanoscale, membrane-bound particles naturally released by virtually all cell types as part of normal cellular communication. Per MISEV2023, they range from approximately 30 to 1000 nm in diameter — though EV populations are inherently heterogeneous, and a high-quality preparation will cluster around a defined size peak, typically 30–200 nm — referring to small EVs. They carry a complex molecular cargo — including proteins, lipids, nucleic acids (such as miRNA and mRNA), and bioactive signaling molecules. EVs function as endogenous intercellular messengers: they are taken up by recipient cells, where their cargo can modulate gene expression, influence inflammatory signaling, and support cellular repair mechanisms. This biological activity makes EVs an area of substantial scientific and commercial interest across medicine and consumer health. In skin biology specifically, EVs derived from botanical sources have been studied in the peer-reviewed literature for their potential role in supporting antioxidant activity and skin-conditioning properties in keratinocyte and fibroblast populations. The Vesera™ Serum is a cosmetic product — no drug or therapeutic claims are made. Note: The term "exosome" is colloquially used in the broader market but is not precise under current ISEV/MISEV2023 guidelines, which recommend "extracellular vesicle" (EV) as the primary scientific descriptor unless intracellular endosomal origin is experimentally confirmed. BioThera uses "EV" as its primary scientific term throughout all materials. Drag to explore EV composition and corona structure vary by source cell type, isolation method, and biological environment. Manufacturing ## How Does BioThera Solutions Manufacture Plant-Derived EVs? BioThera Solutions uses a validated, closed-loop biomanufacturing workflow — encompassing upstream botanical sourcing, EV isolation, and downstream particle characterization — producing plant-derived EVs to MISEV2023 specifications. The process is engineered for batch-to-batch reproducibility, full traceability, and scalability from research-grade to commercial-grade output. Our EV isolation and purification process is proprietary and IP-protected. Process details are not disclosed publicly. What we can confirm: - Designed for reproducibility and scalability from the ground up - Every production batch undergoes standardized analytical characterization - Ships frozen — cold-chain protocols maintained throughout handling and distribution - Manufacturing trajectory aligned toward GMP and ISO compliance Our Core Moat We know how to produce industrial quantities of plant-derived EVs at the rigour skincare requires. Our biomanufacturing workflow is the infrastructure the EV skincare category has been missing: reproducible, standardized, and engineered from the ground up to support a growing portfolio of dermocosmetic and EV-based skincare applications. ### Quality Control Framework #### Nanoparticle Tracking Analysis (NTA) Particle concentration and size distribution verified per batch — the gold standard for EV characterization under MISEV2023. #### Certificate of Analysis (CoA) Batch-level documentation issued for every production run. #### Cold-Chain Handling Temperature-controlled from manufacturing through delivery. Product ships frozen to ensure EV bioactivity is fully preserved upon arrival. #### MISEV2023-Compliant Characterization Characterization approach fully compliant with the Minimal Information for Studies of EVs (MISEV2023) guidelines published by the International Society for Extracellular Vesicles (ISEV) — the global field standard. Source Material ## Why Plant-Derived EVs? BioThera's platform is built on plant-derived EVs — a deliberate scientific and strategic choice that is cost-effective, 100% sustainable, and entirely ethical. Cost-Effective 100% Sustainable Fully Ethical Cross-Kingdom Biological Communication The capacity of plant-derived EVs to interact with and influence mammalian cellular processes represents an emerging and scientifically important area of EV research. This cross-kingdom biological communication underpins our plant-derived EV skincare platform — and informs every dermocosmetic and EV-based skincare application we are building on top of it. 0 1 ### Abundant Botanical Biomass Plant biomass provides an abundant, low-cost, and renewable upstream resource — no animal or human donor material required for our current product line. This supports scalable, consistent upstream production at a fraction of the cost of mammalian cell culture systems. 0 2 ### Streamlined, Cost-Efficient Production Plant-derived EV production eliminates the bioreactor complexity, contamination risk, and regulatory overhead associated with mammalian cell culture — making it the most commercially viable foundation for industrial-scale EV manufacturing dedicated to skincare and dermocosmetic applications. 0 3 ### Hypo-Allergenic Safety Profile Extensive use of botanical actives in cosmetics provides a well-characterized safety baseline. Plant-derived EVs exhibit a biocompatible profile appropriate for topical dermocosmetic use. 0 4 ### Biologically Active Cargo Plant EVs carry biologically relevant cargo — including small RNA species and signaling molecules — capable of influencing gene-regulatory and cellular signaling pathways in human skin cells. Identified Bioactive Classes ## What Bioactive Cargo Do Plant-Derived EVs Carry? Proteomics characterization of BioThera Solutions's plant-derived EV fraction identified proteins distributed across three functional classes: antioxidant-associated, anti-inflammatory-associated, and wound-healing/regenerative-associated. These payload classes are consistent with the well-documented biological profile of Aloe barbadensis across decades of peer-reviewed literature. BioThera has identified three distinct bioactive payload classes in our plant-derived EVs, confirmed by proteomics analysis. ### Antioxidant Payload Antioxidant-active molecules — including plant-derived phenolic compounds and free radical scavengers — confirmed by proteomics. These attenuate oxidative stress in skin cell populations and support cellular defense mechanisms. ### Skin-Soothing Bioactive Fraction Signaling molecules confirmed by proteomics — compounds studied in cell-based research for their association with skin-soothing and calming properties in keratinocyte and fibroblast populations. ### Skin-Renewal Bioactive Fraction Growth factor-associated molecules and miRNA species confirmed by proteomics — compounds studied in cell-based research for their role in supporting skin cell renewal and conditioning processes. Bioactive payload characterization conducted by proteomics and in accordance with MISEV2023 guidelines. No therapeutic claims are made — the Vesera™ Serum is a cosmetic product regulated under Health Canada Cosmetic Regulations (C.R.C., c. 869). Applications ## One platform. Many applications. The same isolation and characterization workflow supplies every application built on the platform. See what it supplies, which application areas it serves, and how far each one has actually gone. See the applications CURRENT UNDERSTANDING ## How Do Plant-Derived EVs Interact with Human Skin? Current scientific evidence supports EV surface and epidermal interaction as the primary mechanism by which topically applied plant-derived EVs may influence skin biology. BioThera Solutions presents an evidence-stratified model distinguishing well-supported surface interactions from plausible follicular routes, while noting that further research is required to demonstrate passive penetration of intact EV-sized particles (30–1000 nm) across the stratum corneum. Extracellular vesicles are proposed to interact with human skin through multiple pathways — each associated with a distinct level of experimental support. This model distinguishes well-supported surface and epidermal interactions from plausible follicular penetration. Trans-stratum corneum passive diffusion of intact EV-sized particles (30–1000 nm) remains an area where further research is required to demonstrate penetration across the SC. No mechanism depicted is clinically confirmed. Pathway Evidence Levels ✅ Surface / epidermal interaction ⚠️ Follicular route (plausible) ❌ Trans-SC diffusion (further research required) Skin barrier: ~500 Da passive cutoff · EV size 30–1000 nm → exceeds threshold Evidence-stratified pathway model — no mechanism is clinically confirmed. This illustration maps proposed interaction pathways across distinct levels of experimental support. Surface and epidermal interaction (stratum corneum surface, keratinocytes) is well-supported in the botanical EV literature. Follicular penetration via the hair follicle shaft and sebaceous duct is a plausible and increasingly studied route for nanoscale particles. Trans-stratum corneum passive diffusion of intact EV-sized particles (30–1000 nm) remains an active area of investigation — further research is required to demonstrate passive penetration across the SC. Anatomical accuracy & site-of-effect framing. Layer proportions are calibrated to H&E histological reference standards. The epidermis is rendered at 3× its true relative scale. Vasculature is shown in longitudinal view; hair follicle, sebaceous gland, eccrine sweat gland, and dermal innervation are anatomically positioned. EV opacity attenuates with depth to reflect decreasing penetration confidence. The dermis is marked as the proposed site of biological effect — surface interactions may initiate signalling cascades that propagate to deeper dermal cell populations, independent of whether EVs physically traverse the stratum corneum. ============================================================================== # Applications of the EV platform Source: https://biotherasolutions.com/applications ============================================================================== Applications of the EV Platform # One Platform. Many Applications. BioThera isolates and characterizes plant-derived extracellular vesicles at manufacturing scale. What those vesicles are formulated into is an application question, not a platform one. Below are the areas the platform is built to serve — and how far each one has actually gone. What the platform supplies ## Characterized material, documented batch by batch. Material ### Characterized EV bulk Plant-derived extracellular vesicles isolated at manufacturing scale, counted by Nanoparticle Tracking Analysis and characterized against the MISEV2023 marker framework. Documentation ### Batch-specific CoA Every batch ships with its own Certificate of Analysis: particle concentration, EV marker panel, and contamination screen. MISEV2023 disclosures available on request. Logistics ### Cold-chain delivery Shipped directly from the BioThera Solutions facility in Ottawa, Ontario, in cold-chain packaging sized to the destination. No distributor handoff. How the material is made: Our technology Application areas ## Where the platform applies — and how far it has gone. Maturity reflects how far BioThera has taken each area, not what extracellular vesicles are claimed to do in the literature. Areas marked as research directions have no BioThera product and no published timeline. Commercial ### Skincare & dermocosmetics Topical formulation of characterized plant-derived EVs for professional skin care. Supplied to verified dermatology and aesthetic medicine clinics in Canada under our Vesera™ brand. Not in general distribution. In evaluation ### Clinical dermatology An active safety and efficacy study is underway with practicing dermatologist partners. Clinics evaluating the material receive the batch-specific Certificate of Analysis behind every shipment. Research direction ### Wound & barrier repair EV cargo classes associated with wound healing appear in our proteomics data and in the plant-EV literature. We have characterization data; we do not yet have outcome data. Research direction ### Regenerative medicine The biomanufacturing and characterization requirements of regenerative applications are the ones this platform was engineered against. No BioThera product exists in this space. Research direction ### Drug delivery EVs are a phospholipid-bilayer delivery vehicle. Whether ours can carry an exogenous payload at specification is an open question we are equipped to answer. Brands built on the platform ™ ## Vesera™ — our dermocosmetic brand. Vesera™ is BioThera’s dermocosmetic brand: plant-derived extracellular vesicles from Aloe barbadensis, formulated for professional skin care. It is a Health Canada-notified cosmetic, characterized to MISEV2023 on every batch. Vesera™ is one application of the platform — not the company. Join the Vesera™ early-access list For clinics: ordering, CoA and cold chain Regulatory & Certifications ## Standards we manufacture to Complete ### Health Canada — Cosmetic Regulations (C.R.C., c. 869) Fully compliant with Canada's Cosmetic Regulations under the Canada Consumer Product Safety Act (C.R.C., c. 869). Canadian market authorized. Complete ### MISEV2023 — Characterization Compliant Fully compliant with the Minimal Information for Studies of Extracellular Vesicles (MISEV2023) guidelines — the global standard published by the International Society for Extracellular Vesicles (ISEV). Complete ### Leaping Bunny Cruelty-Free Certification Active certification. No animal testing at any stage of production or supply chain. In Progress ### GMP/ISO-Aligned Manufacturing Manufacturing process under active development toward GMP and ISO alignment as we scale our dermocosmetic and EV-based skincare portfolio. Planned ### FDA — FD&C Act / MoCRA Alignment Formulation is aligned with the Federal Food, Drug, and Cosmetic Act (FD&C Act, 21 U.S.C. § 361) and the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). U.S. market entry is planned for a future phase — facility registration and full MoCRA compliance will be pursued at that time. Waitlist ## Be First. The Vesera™ Serum is in active clinical evaluation — not yet in general distribution. Join the early access list and we will notify you the moment clinic access opens. Tell us who you are so we can prioritize the right pathway. BioThera supplies cosmetic-grade material today. Vesera™ is a cosmetic under Health Canada Cosmetic Regulations and is not intended to diagnose, treat, cure, or prevent any disease. Application areas marked as research directions are not products, are not offered for sale, and carry no therapeutic claim. Work with the platform ## Talk to us about supply or co-development. Whether you need characterized EV material with documentation behind it, or want to explore an application that is not on this page, start with a conversation. Contact the team ============================================================================== # MISEV2023 — Pillar primer (named contributor) Source: https://biotherasolutions.com/resources/misev2023 ============================================================================== Resources / MISEV2023 EV consensus standards # MISEV2023, in plain working language — from a named contributor. The Minimal Information for Studies of Extracellular Vesicles 2023 update (MISEV2023) is the international consensus standard for EV research, published by the International Society for Extracellular Vesicles. BioThera's founder is a named contributor to the 2023 consortium. This is what the guideline asks of a defensible EV product. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions. Named contributor, MISEV2023. What it is ## The field's quality framework, not a marketing badge MISEV stands for Minimal Information for Studies of Extracellular Vesicles . First published by the International Society for Extracellular Vesicles in 2014, updated in 2018, and substantially rewritten as MISEV2023 with a multi-year consortium of EV researchers across academia and industry — BioThera's founder among them — the document defines the minimum characterization, reporting, and quality controls a study or product needs to defensibly claim it works with extracellular vesicles. The guideline is deliberately framed as a floor, not a ceiling. A preparation that meets MISEV2023 has demonstrated, on a per-batch basis, that it contains particles of the expected size, that those particles carry markers of EV origin, that they are not contaminated with non-vesicular material that would confound interpretation, and that the isolation method behind the preparation has been disclosed in enough detail to be meaningful. Most commercial exosome skincare products do not meet this floor. That is not a marketing slight; it is a working observation about an industry that grew faster than the characterization infrastructure under it. MISEV2023 is the field's collective answer to that gap. The framework ## Five working requirements that MISEV2023 imposes The 2023 update is long. These five anchor what an EV product has to demonstrate to be defensible. - 01 ### Multiple, complementary characterization methods No single measurement is sufficient. EV characterization requires orthogonal methods — at minimum, a single-particle counting method (typically NTA), a marker panel covering transmembrane and cytosolic EV-associated proteins, an absence-of-contaminants screen, and morphology confirmation (TEM). - 02 ### Method-level transparency Isolation method must be named and characterized for its impact on the final preparation. "Proprietary isolation" without method-of-action disclosure to qualified partners is not MISEV2023-compliant. - 03 ### Batch-specific reporting Particle concentration, marker panel data, and contamination screen results must be reported per production batch — not as a generic product specification. A Certificate of Analysis describes the batch in the box, not the platform in the abstract. - 04 ### Source-appropriate marker selection Mammalian tetraspanin markers (CD9, CD63, CD81) and ESCRT-associated cytosolic markers (TSG101, Alix) were defined for mammalian EV systems. Plant-derived EVs require markers appropriate to plant biology and a contamination screen attentive to plant-specific co-purifying material. - 05 ### Honest reporting of limits Where measurements have known biases (NTA under-counting at very small sizes, marker enrichment that overlaps with non-EV particles), MISEV2023 expects acknowledgement of those limits rather than over-interpretation. The guideline is a quality framework, not a marketing one. Go deeper ## The cluster — three working articles on the load-bearing variables Three deeper pieces working through the variables that MISEV2023 treats as non-negotiable, each written to the same editorial voice as the broader site: field-precise, conservative on claims, honest about limits. Isolation ### Why isolation method matters under MISEV2023 MISEV2023 does not endorse a single isolation method. It requires that whichever method is used be disclosed, characterized, and accounted for in the product specification. Three working consequences for EV product evaluation. Counting ### NTA versus other particle-counting methods under MISEV2023 Why Nanoparticle Tracking Analysis became the field standard, what it does well, where it fails, and which orthogonal methods MISEV2023 expects alongside it. Markers ### EV marker panels explained — CD9, CD63, CD81, TSG101, Alix, and the absence-of-contaminants requirement What each marker actually tells you about an EV preparation, why no single marker is sufficient, and the contamination screen MISEV2023 expects alongside positive markers. Why this matters ## For clinicians, partners, and investors MISEV2023 is the closest thing the EV field has to a quality contract. A manufacturer that operates inside it has, by construction, a defensible story to tell when a clinician asks what is in the bottle, when a procurement team asks what the CoA actually proves, or when a regulator asks what the basis is for a particular claim. A manufacturer that operates outside it does not have that story, regardless of marketing copy. This pillar and the three supporting articles exist because we think every clinician evaluating an EV product should be able to ask MISEV2023-grade questions of their suppliers, including us, and get answers. The framework on this page is also the framework BioThera operates against internally — every Vesera™ batch ships with characterization that maps to it. Apply the framework ## Use this when evaluating any EV product The clinician-facing evaluation guide turns these requirements into a five-question checklist for product selection. The For Clinicians hub walks through procurement, CoA workflow, and cold-chain logistics. Evaluation framework For Clinicians hub ============================================================================== # MISEV2023 — Why isolation method matters Source: https://biotherasolutions.com/resources/misev2023/why-isolation-method-matters ============================================================================== Resources / MISEV2023 MISEV2023 # Why isolation method matters under MISEV2023 MISEV2023 does not endorse a single isolation method. It requires that whichever method is used be disclosed, characterized, and accounted for in the product specification. Three working consequences for EV product evaluation. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions MISEV2023 is often summarised as "the EV characterization standard." That undersells it. The guideline is also, less famously, an isolation-method-honesty document. Section after section returns to the same working point: tell the reader exactly how the EVs were separated from their source material, characterize what came out of that workflow, and report it. The method is not background detail. It is part of the product specification. This is the framing most commercial EV product pages omit. "Isolated from species X by proprietary methods" appears on a non-trivial fraction of exosome skincare labels. Under MISEV2023, that sentence is incomplete by design. ## What MISEV2023 actually requires about isolation The 2023 update sharpens three asks from earlier MISEV iterations. First, the method has to be named. Ultracentrifugation, density gradient, ultrafiltration, size-exclusion chromatography (SEC), tangential flow filtration (TFF), polymer-based precipitation, and immunoaffinity capture are not interchangeable; the choice has downstream consequences and the consumer of the preparation is owed the information. Second, the method has to be characterized. It is not enough to assert that ultracentrifugation produces a "clean" preparation. The guideline expects the manufacturer to demonstrate, with measurements, what the chosen workflow yields in terms of particle concentration, marker enrichment, contamination, and where applicable, the integrity of the biomolecular corona and the absence of non-vesicular contaminants. These measurements should be batch-specific. Third, where the method strips, modifies, or co-purifies something that affects the active fraction, that has to be disclosed in the characterization record. "We used ultracentrifugation and confirmed the resulting preparation by NTA, Western for CD9 and CD63, and SDS-PAGE for soluble protein contamination" is a defensible disclosure. "Proprietary isolation" is not. ## Why method changes the product Two preparations from identical biomass, separated by different methods, are not the same product. The mechanism is straightforward and has been demonstrated experimentally in our own published work. Ultracentrifugation applies high gravitational force over extended periods. It pellets EVs efficiently but also shears more labile components of the biomolecular corona, fragments fragile vesicle subpopulations, and co-pellets contaminating non-vesicular protein aggregates that travel with the EV fraction into downstream characterization. The resulting product is often particle-rich but corona-altered. Ultrafiltration uses a size-cutoff membrane and depends on pressure-driven flow. It preserves more of the soft corona because the EVs are not subjected to high g-forces, but it can introduce adsorption losses to the membrane material and concentration-dependent aggregation effects. SEC preserves the corona more gently than either, with its own trade-offs in dilution, throughput, and yield. TFF combines size selection with continuous flow and is the workflow most amenable to scale, with characterization implications of its own. None of these methods is wrong. They produce different preparations from the same starting material. MISEV2023's point is that the manufacturer has to know which one they used and characterize what came out of it. A "proprietary" answer leaves the buyer guessing about a load-bearing variable. ## Three implications for evaluating an EV product First, source biomass is not a complete specification. "Aloe-derived EVs" or "platelet-derived exosomes" tells the buyer the species and tissue. It does not tell the buyer what the surface chemistry, particle integrity, or corona profile of the final product looks like. Source plus isolation method together define the active particle. Second, batch consistency requires control over both source variability and processing variability. A manufacturer that has not characterized how its isolation method shapes the corona is not controlling one of the two main drivers of lot-to-lot drift. Asking which method is used, and how it was validated, is a legitimate clinician question. Third, "proprietary" should not mean "undisclosed." Method-level intellectual property is real and worth protecting. MISEV2023 does not ask a manufacturer to publish a step-by-step protocol on a marketing page. It asks for a defensible disclosure to qualified clinical and manufacturing partners under appropriate agreement. The default is "characterized and disclosed under terms," not "characterized in private." ## What BioThera does and why Vesera™ is produced through a gentle, scalable isolation workflow designed to avoid the mechanical and chemical damage that more aggressive methods can inflict on plant-derived EVs. The detailed protocol is proprietary and IP-protected. Process transparency documentation, including characterization of how the workflow preserves the biomolecular corona, is available to qualified manufacturing partners under NDA. Every production batch ships with a CoA reporting NTA-measured particle concentration, marker panel data, and the absence of relevant contaminants. The reason the workflow gets discussed alongside the product, rather than buried under "proprietary," is that MISEV2023 makes it a load-bearing variable. The guideline's authors, this one included, designed it that way. ## What this looks like in practice A clinician evaluating a candidate EV product can ask four questions that operationalise MISEV2023's isolation-disclosure requirement: - Which isolation method was used to produce this batch? - Has the method been validated for impact on particle integrity, marker enrichment, and biomolecular corona retention? - Are batch-specific characterization data (NTA, marker panel, contamination screen) available? - Is the level of process transparency on offer appropriate for the product's intended use — over-the-counter cosmetic versus professional-use clinical product versus investigational therapeutic? A manufacturer that can answer these four questions cleanly is operating inside MISEV2023's intent. A manufacturer that cannot is, regardless of marketing claims, producing a preparation whose composition is partly accidental. References ## Primary sources - Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, St-Denis-Bissonnette F, et al. . Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - St-Denis-Bissonnette F, et al. . Ultracentrifugation and ultrafiltration differentially alter the composition and functionality of the biomolecular corona of extracellular vesicles . Journal of Extracellular Biology , 2026 . doi.org/ 10.1002/jex2.70132 - Théry C, Witwer KW, Aikawa E, et al. . Minimal information for studies of extracellular vesicles 2018 (MISEV2018) . Journal of Extracellular Vesicles , 2018 . doi.org/ 10.1080/20013078.2018.1535750 - Sidhom K, Obi PO, Saleem A. . A review of exosomal isolation methods: is size exclusion chromatography the best option? . International Journal of Molecular Sciences , 2020 . doi.org/ 10.3390/ijms21186466 Related reading ## Continue exploring MISEV2023 ### NTA versus other particle-counting methods under MISEV2023 Why Nanoparticle Tracking Analysis became the field standard, what it does well, where it fails, and which orthogonal methods MISEV2023 expects alongside it. MISEV2023 ### EV marker panels explained — CD9, CD63, CD81, TSG101, Alix, and the absence-of-contaminants requirement What each marker actually tells you about an EV preparation, why no single marker is sufficient, and the contamination screen MISEV2023 expects. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # MISEV2023 — NTA vs other counting methods Source: https://biotherasolutions.com/resources/misev2023/nta-vs-other-counting-methods ============================================================================== Resources / MISEV2023 MISEV2023 # NTA versus other particle-counting methods under MISEV2023 Nanoparticle Tracking Analysis became the field standard because it measures the right thing the right way. MISEV2023 still requires orthogonal confirmation. Here is what each method does, where it fails, and what the guideline expects. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Every EV product specification rests on a number of particles per millilitre. That number has to come from somewhere. MISEV2023 takes a clear position on where: a primary single-particle measurement, ideally orthogonal, with the method named and the limitations acknowledged. Nanoparticle Tracking Analysis ended up as the field default because, of the available options, it satisfies that brief best. It is also not infallible, and the guideline is explicit about why. ## Why NTA NTA tracks the Brownian motion of individual nanoparticles in suspension under a focused laser. The instrument records a video of each particle's diffusion, fits the trajectories to the Stokes–Einstein equation, and outputs a per-particle hydrodynamic diameter and a concentration estimate. The measurement is single-particle, label-free, and operates in solution at physiologically relevant concentrations. Three properties earned it the default status: - Single-particle resolution. Bulk methods, like dynamic light scattering, fit a population to an aggregate signal and lose the distribution. NTA keeps it. - Wide dynamic range across EV-relevant sizes. NTA can resolve particles roughly from 50 nm to 1,000 nm reliably on well-calibrated instruments, which covers the bulk of the EV size space, including both exosomes and most microvesicles. - Workflow compatibility. Sample prep is minimal, runs are fast, and the method tolerates buffers that occur in EV preparations. For a CoA-grade particle concentration on a per-batch basis, NTA is currently the path of least resistance among methods that meet MISEV2023's reporting bar. ## Where NTA falls short Anyone who has run NTA on real EV preparations has seen its limits. MISEV2023 names them. NTA does not distinguish vesicles from non-vesicular particles of similar size. A lipoprotein, a protein aggregate, or a polymer micelle in the size range looks identical to a small EV in the trajectory data. This is why MISEV2023 pairs particle counting with marker enrichment and contamination screening — the count alone says "there are particles," not "those particles are EVs." NTA is sensitive to operator parameters and instrument-specific differences. Camera gain, detection threshold, and analysis settings all influence the resulting number. Cross-instrument comparison without standardised parameters can produce reportable differences from the same preparation. The literature has direct head-to-head comparisons that quantify this. NTA underestimates the smallest EVs. Particles below approximately 50 nm produce weaker scattering signal and may fall below the instrument's detection threshold, depending on refractive index. For samples enriched for very small exosomes, NTA can systematically undercount the lower tail. NTA does not measure refractive index directly. Concentration estimates assume reasonable optical properties for the particle population. EVs and non-EV nanoparticles of similar size can differ in refractive index in ways that bias the absolute count. ## What MISEV2023 expects alongside NTA MISEV2023 frames characterization as an orthogonal-methods exercise. No single measurement is sufficient. The guideline names the alternatives most useful in combination with NTA. Tunable Resistive Pulse Sensing (TRPS). Counts and sizes particles individually as they pass through a nanopore. It is orthogonal to NTA because the physics is different — a current-blockade measurement rather than an optical-scattering one — and is less sensitive to refractive index. TRPS struggles at higher throughput and with the smallest particles, but it makes a strong cross-check against an NTA result. High-resolution flow cytometry with a fluorescent label. When the EVs are labelled for a specific marker, flow cytometry can count vesicles that carry the marker, not just particles of the right size. This is what makes flow cytometry a useful follow-up after NTA: it converts a particle count into a specifically-marker-positive particle count. Dynamic light scattering (DLS). Bulk-measurement method that delivers a hydrodynamic size distribution and is fast to run as a sanity check. DLS does not give per-particle data and is biased toward larger particles in heterogeneous samples. Useful for quick QC, not for primary concentration claims. Transmission electron microscopy (TEM). Visualises individual EVs, confirms morphology, and is the gold standard for "do these look like vesicles." Not a counting method at scale, but indispensable for batch-release confirmation that the particles in the preparation have the expected bilayer-membrane appearance. ## What this looks like in a real CoA A defensible Certificate of Analysis reports an NTA-measured particle concentration with its standard deviation across replicate measurements, the NTA instrument and parameter set used, and at least one orthogonal confirmation. The orthogonal confirmation does not have to be exhaustive on every batch; it has to be performed often enough that the manufacturer can show the relationship between methods has been characterized. Vesera™'s batch-specific CoA reports NTA-measured particle concentration, marker enrichment on a defined panel, an absence-of-contaminants screen, and TEM confirmation of morphology. The number on the label is the number that came out of that workflow, with the workflow declared. The orthogonal methods are not decorative; they exist because NTA on its own is not enough to satisfy MISEV2023. ## What clinicians and partners can ask Three questions cut through marketing copy on this point: - Which instrument and parameter set were used for the NTA measurement on this batch, and how reproducible is the number across replicate runs? - Has the relationship between the NTA-reported count and at least one orthogonal method (TRPS, flow cytometry, TEM) been characterized for this manufacturing workflow? - Is the reported count corrected for known biases, particularly the lower-tail under-counting that affects very-small-EV-enriched samples? A manufacturer that has thought about NTA the way MISEV2023 asks can answer all three. A manufacturer that has not, cannot. References ## Primary sources - Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, St-Denis-Bissonnette F, et al. . Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - Bachurski D, Schuldner M, Nguyen PH, et al. . Extracellular vesicle measurements with nanoparticle tracking analysis: an accuracy and repeatability comparison between NanoSight NS300 and ZetaView . Journal of Extracellular Vesicles , 2019 . doi.org/ 10.1080/20013078.2019.1596016 - Vogel R, Coumans FAW, Maltesen RG, et al. . A standardized method to determine the concentration of extracellular vesicles using tunable resistive pulse sensing . Journal of Extracellular Vesicles , 2016 . doi.org/ 10.3402/jev.v5.31242 - Welsh JA, Van Der Pol E, Bettin BA, et al. . Towards defining reference materials for measuring extracellular vesicle refractive index, epitope abundance, size and concentration . Journal of Extracellular Vesicles , 2020 . doi.org/ 10.1080/20013078.2020.1816641 Related reading ## Continue exploring MISEV2023 ### Why isolation method matters under MISEV2023 MISEV2023 does not endorse a single isolation method. It requires that whichever method is used be disclosed, characterized, and accounted for in the product specification. MISEV2023 ### EV marker panels explained — CD9, CD63, CD81, TSG101, Alix, and the absence-of-contaminants requirement What each marker actually tells you about an EV preparation, why no single marker is sufficient, and the contamination screen MISEV2023 expects. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # MISEV2023 — EV marker panels explained Source: https://biotherasolutions.com/resources/misev2023/marker-panels-explained ============================================================================== Resources / MISEV2023 MISEV2023 # EV marker panels explained — CD9, CD63, CD81, TSG101, Alix, and the absence-of-contaminants requirement MISEV2023 asks for a marker panel, not a single marker. What CD9, CD63, CD81, TSG101, and Alix actually tell you about a preparation, why no single one is sufficient, and the contamination screen the guideline expects alongside them. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions MISEV2023 is most often misquoted on the marker question. The common shorthand — "EVs have CD9, CD63, and CD81 on them" — is not what the guideline says. The guideline says that demonstrating a preparation is EV-enriched requires a panel of markers covering several categories, and that the panel choice depends on what is being claimed about the preparation. The single-marker positive result, especially on a Western blot, is not sufficient evidence on its own. Understanding why is the difference between a defensible characterization record and a marketing-grade one. ## What the canonical markers actually are MISEV2023 organises EV markers into three working categories. Category 1 — Transmembrane EV-associated proteins. The tetraspanins CD9, CD63, and CD81 are the canonical examples. They are enriched in EVs across many biogenesis routes and serve as positive markers that the preparation contains material of EV origin. Different EV subpopulations express the three tetraspanins to different extents, which is also informative. Category 2 — Cytosolic proteins recoverable in EVs. TSG101 and Alix are the canonical examples. Both are associated with the ESCRT machinery involved in multivesicular body biogenesis. Their presence in a preparation supports an exosome (MVB-derived) origin and helps distinguish exosomes from microvesicles, which bud from the plasma membrane and are typically lower in ESCRT-associated proteins. Category 3 — Markers of non-EV contaminants. This is the category most often skipped in commercial characterization. MISEV2023 expects evidence of the absence of contamination — typically high-density lipoproteins (apolipoproteins like APOA1, APOB), serum albumin, and cellular debris markers, depending on the source biomass. A preparation that is enriched for CD9 but also enriched for apolipoproteins is co-purifying lipoproteins along with the vesicles. That is information the buyer needs. ## Why no single marker is sufficient Three reasons, all of them load-bearing. First, no marker is exclusively expressed by EVs. CD9, CD63, and CD81 are enriched in EVs relative to whole-cell lysates, but they are also present on cellular membranes and in cellular subcompartments. A Western band for CD9 in a preparation tells you the preparation contains CD9-bearing material. It does not, on its own, tell you that material is exosomes versus, for example, plasma-membrane fragments. Second, no marker is uniformly expressed across all EV subpopulations. Different EV-producing cells release vesicles with different marker profiles. An exosome population enriched for CD63 might be relatively depleted of CD9. A preparation negative for one tetraspanin is not necessarily not-EVs — it might be EVs of a subtype that does not strongly express that marker. This is why MISEV2023 expects a panel. Third, contamination is invisible to single-marker positive testing. A preparation can be CD9-positive, TSG101-positive, look great on a Western, and still co-purify a substantial fraction of non-vesicular contaminating particles that drive the bulk of the measured biological activity. Without an absence-of-contaminants screen, the positive markers tell only half the story. ## What plant-derived EVs require differently The canonical tetraspanin and ESCRT markers were defined in mammalian systems. Plant-derived EVs (PDEVs) have a partially overlapping, partially distinct molecular toolkit, and the field is still working out which markers serve the same diagnostic role for plant-source preparations. MISEV2023 explicitly acknowledges this. For PDEV preparations, the guideline expects characterization using markers appropriate to the source — typically a combination of conserved protein homologues, plant-specific membrane components, and a strict contamination panel that is especially attentive to plant cell-wall fragments and protein-pigment complexes that travel with the vesicles through some isolation workflows. Calling a plant preparation an "exosome" on the basis of mammalian tetraspanin homology alone is exactly the kind of shortcut MISEV2023 was written against. For Aloe barbadensis-derived EVs, the working characterization panel in our process spans plant-EV-relevant protein markers identified in published proteomic surveys of PDEVs, an absence-of-contaminants screen targeting plant-cell-wall components and chloroplastic remnants, and TEM confirmation of bilayer-membrane morphology consistent with a vesicular preparation. The combination, not any one of these elements, is what supports the EV-enrichment claim. ## What a defensible panel looks like on a CoA Under MISEV2023, a marker section on a Certificate of Analysis should include, at minimum: - At least one Category 1 marker (transmembrane EV-associated protein) reported as positive with a clear band on the appropriate detection method. - At least one Category 2 marker (cytosolic EV-associated, e.g. TSG101 or Alix for mammalian preparations) — relevance depends on the biogenesis claim being made. - An absence-of-contaminants screen targeting the contaminants most likely to co-purify given the source biomass and isolation method. - Source-appropriate substitutions for PDEV preparations, using markers validated for plant EVs rather than mammalian tetraspanins alone. - Method-of-detection disclosure — Western blot, ELISA, flow cytometry, mass spectrometry — with sufficient information that a third party can interpret the result. A CoA that reports "CD9 positive" with no contamination screen, no second marker, and no detection method is not characterizing the preparation. It is asserting a single fact that, on its own, does not support the conclusions a marketing page draws from it. ## What clinicians and partners can ask Three questions on the marker panel, paralleling the ones on isolation and counting: - Which markers are reported on the batch-specific CoA, and which MISEV2023 category does each one address? - Is an absence-of-contaminants screen included on every batch, and what does it target? - For plant-derived preparations, are the markers chosen appropriate to plant biology, or were mammalian markers used as a stand-in? The answers, taken together with the isolation method and the particle count, are what a defensible EV product specification consists of. Anything less is a partial picture, and MISEV2023 is explicit about not wanting to settle for that. References ## Primary sources - Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, St-Denis-Bissonnette F, et al. . Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - Kowal J, Arras G, Colombo M, et al. . Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes . PNAS , 2016 . doi.org/ 10.1073/pnas.1521230113 - Jeppesen DK, Fenix AM, Franklin JL, et al. . Reassessment of exosome composition . Cell , 2019 . doi.org/ 10.1016/j.cell.2019.02.029 - Pinedo M, de la Canal L, de Marcos Lousa C. . A call for Rigor and standardization in plant extracellular vesicle research . Journal of Extracellular Vesicles , 2021 . doi.org/ 10.1002/jev2.12048 Related reading ## Continue exploring MISEV2023 ### Why isolation method matters under MISEV2023 MISEV2023 does not endorse a single isolation method. It requires that whichever method is used be disclosed, characterized, and accounted for in the product specification. MISEV2023 ### NTA versus other particle-counting methods under MISEV2023 Why Nanoparticle Tracking Analysis became the field standard, what it does well, where it fails, and which orthogonal methods MISEV2023 expects alongside it. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Glossary of EV terminology Source: https://biotherasolutions.com/resources/glossary ============================================================================== Resources / Glossary EV Terminology Reference # The extracellular vesicle glossary. Field-precise definitions for the terminology that appears across this site and across the EV literature. Each term has a stable anchor — copy the URL to share a definition directly. Jump to Extracellular vesicle (EV) # A nanoscale, bilayer-membrane-enclosed particle naturally secreted by cells. The umbrella class containing exosomes, microvesicles (ectosomes), and apoptotic bodies — distinguished from each other by biogenesis route, not by size alone. Related: Exosome , Microvesicle (ectosome) , Apoptotic body Exosome # An EV subpopulation that originates from the multivesicular body (MVB) pathway and is released into the extracellular space when an MVB fuses with the plasma membrane. Typically 30–150 nm. A product can only be called an exosome if biogenesis is demonstrated — size alone is insufficient. Related: Multivesicular body (MVB) , Extracellular vesicle (EV) , EV biogenesis Microvesicle (ectosome) # An EV subpopulation that buds directly outward from the plasma membrane. Typically 100–1,000 nm. Distinct from exosomes by origin even when size ranges overlap. Related: Extracellular vesicle (EV) , EV biogenesis Apoptotic body # An EV subpopulation released during programmed cell death. Typically 1–5 µm. Not the relevant active fraction in dermocosmetic or regenerative EV products. Related: Extracellular vesicle (EV) Plant-derived extracellular vesicle (PDEV) # EVs isolated from plant tissues (e.g. Aloe barbadensis leaf parenchyma) rather than mammalian cells. Distinct from animal-derived EVs in safety profile, regulatory pathway, and scalability. The starting material for BioThera's Vesera™ Serum. Related: Vesera™ serum , Aloe barbadensis , Cross-kingdom signalling Vesera™ serum # BioThera's professional-grade plant-derived EV dermocosmetic serum, formulated from Aloe barbadensis-derived EVs. Health Canada cosmetic notification complete; characterized to MISEV2023 standards on every batch. Related: Plant-derived extracellular vesicle (PDEV) , MISEV2023 , Aloe barbadensis MISEV2023 # Minimal Information for Studies of Extracellular Vesicles, 2023 update — the field-defining international consensus guidelines for EV research published by the International Society for Extracellular Vesicles (ISEV). Specifies the minimum characterization, reporting, and quality controls required to defensibly call a preparation an EV product. Related: ISEV , Certificate of Analysis (CoA) , EV-associated marker panel ISEV # International Society for Extracellular Vesicles — the global scientific society that authors and maintains the MISEV consensus guidelines and serves as the primary professional body for EV research. Related: MISEV2023 EV biogenesis # The intracellular pathway by which an EV is produced. The three recognised routes — multivesicular body fusion (exosomes), plasma-membrane budding (microvesicles), and apoptotic blebbing (apoptotic bodies) — are how the field distinguishes EV subpopulations. Biogenesis, not size, defines an exosome. Related: Exosome , Microvesicle (ectosome) , Multivesicular body (MVB) Multivesicular body (MVB) # A late endosomal compartment containing intraluminal vesicles. When an MVB fuses with the plasma membrane, those intraluminal vesicles are released to the extracellular space as exosomes. Related: Exosome , EV biogenesis Nanoparticle Tracking Analysis (NTA) # A light-scattering measurement that sizes and counts nanoparticles in suspension by tracking their Brownian motion. The field standard for reporting EV particle concentration (particles/mL) per batch. Required orthogonal characterization under MISEV2023. Related: MISEV2023 , Particle concentration , EV characterization EV-associated marker panel # A set of protein markers — CD9, CD63, CD81 (tetraspanins); TSG101 and Alix (ESCRT-associated); plus markers for absence-of-contaminants — used together to demonstrate that a preparation is enriched for EVs rather than for cell debris, protein aggregates, or other nanoparticles. Related: MISEV2023 , Certificate of Analysis (CoA) # A batch-specific quality document reporting the measured properties of a single production lot: particle concentration (NTA), EV marker panel, contamination screen, isolation method, and storage conditions. A generic product specification sheet is not a CoA — it must be batch-specific. Related: MISEV2023 , Nanoparticle Tracking Analysis (NTA) , EV characterization Biomolecular corona # The layer of proteins, lipids, and other biomolecules that adsorb to an EV's outer membrane and travel with it through purification and into the final product. The corona is part of the active ingredient. Two preparations from the same biomass can carry different coronas depending on isolation method. Related: Isolation method , EV characterization Isolation method # The technique used to separate EVs from their source biomass. Common methods include ultracentrifugation, density gradient, ultrafiltration, size-exclusion chromatography, and tangential flow filtration. Different methods preserve or strip the biomolecular corona to different extents, which changes what the final product actually is. Related: Biomolecular corona , Ultracentrifugation , Ultrafiltration , MISEV2023 Ultracentrifugation # High-speed centrifugation (>100,000 × g) used to pellet EVs. Effective at enrichment but mechanically stressful — can strip components of the biomolecular corona and aggregate vesicles. Disclosed in the CoA where applicable. Related: Isolation method , Biomolecular corona Ultrafiltration # Pressure-driven separation across a porous membrane sized to retain EVs while letting smaller solutes pass. Gentler than ultracentrifugation; corona retention depends on membrane choice and conditions. Related: Isolation method , Biomolecular corona Particle concentration # EV count per unit volume, typically reported as particles/mL by NTA. A measured, batch-specific number — not a marketing estimate. Vesera™ reports approximately 30 billion particles/mL. Related: Nanoparticle Tracking Analysis (NTA) , Certificate of Analysis (CoA) Aloe barbadensis # The botanical species (commonly 'aloe vera') whose leaf parenchyma is the biomass source for Vesera™. Aloe barbadensis-derived EVs carry an antioxidant-, anti-inflammatory-, and wound-healing-associated proteome consistent with the documented biological profile of the parent plant. Related: Plant-derived extracellular vesicle (PDEV) , Vesera™ serum Cross-kingdom signalling # Uptake and biological effect of plant-derived EVs by mammalian cells. Preclinical evidence supports cargo transfer and modulation of mammalian gene expression in model systems. Clinical translation in human skin is an active area; BioThera's framing treats this as supported in vitro and under evaluation in vivo. Related: Plant-derived extracellular vesicle (PDEV) Health Canada Cosmetic Notification # The mandatory notification a cosmetic manufacturer must file with Health Canada under the Cosmetic Regulations (C.R.C., c. 869) within ten days of first sale in Canada. Vesera™ is a notified cosmetic under this framework. Related: MoCRA , MoCRA # Modernization of Cosmetics Regulation Act of 2022 — the framework requiring US cosmetic facility registration and product listing with the FDA. BioThera's FDA / MoCRA alignment is in progress; direct US clinic supply opens at completion. Related: Health Canada Cosmetic Notification , TRL (Technology Readiness Level) # A 1–9 scale used by NASA, ESA, and Industry Canada to describe how mature a technology is. BioThera's dermocosmetic application currently operates at TRL 7–8 — system prototype demonstrated in operational environment via dermatologist-led clinical evaluation, with manufacturing process complete and qualified under Health Canada Cosmetic Regulations. CD9, CD63, CD81 (tetraspanins) # Membrane proteins commonly enriched on EVs. Together they are one of the canonical EV-positive marker sets used to demonstrate that a preparation is EV-enriched. Related: EV-associated marker panel , MISEV2023 TSG101 / Alix # ESCRT-machinery-associated proteins involved in MVB biogenesis. Detection in a preparation supports an exosome (MVB-derived) origin and is part of the standard MISEV2023 marker panel. Related: EV-associated marker panel , Multivesicular body (MVB) Hollow-fibre bioreactor # A bioreactor format in which cells or plant tissue are cultured against semi-permeable hollow fibres, enabling perfusion at high cell density and continuous harvest of secreted EVs. The format BioThera builds toward for scalable EV biomanufacturing. Related: EV biomanufacturing EV biomanufacturing # The full upstream-plus-downstream production of EV products at scale: biomass sourcing, culture or extraction, isolation, characterization, formulation, fill-finish, and batch release. BioThera's platform is full-stack across that pipeline. Related: Hollow-fibre bioreactor , Isolation method , Vesera™ serum EV characterization # The set of orthogonal measurements used to describe an EV preparation: particle size and count (NTA), morphology (TEM), protein markers (Western blot, proteomics), and contamination screening. MISEV2023 specifies the minimum reporting requirements. Related: MISEV2023 , Nanoparticle Tracking Analysis (NTA) , EV-associated marker panel , Certificate of Analysis (CoA) Cold-chain integrity # Maintenance of a defined temperature range from manufacturer to point of use. Required for biologically active EV preparations to preserve membrane and corona integrity. Verifiable via packaging, shipping records, and where required, transit excursion logs. Related: Certificate of Analysis (CoA) PRP (platelet-rich plasma) # An autologous blood-derived preparation enriched for platelets and platelet growth factors. Comparable to EV serums in that both deliver growth-factor-rich biological inputs to skin; differs in origin, batch consistency, regulatory pathway, and delivery format. Treated as complementary rather than competitive in BioThera's editorial framing. Related: Keep reading ## Long-form context on these terms Most of these definitions show up across the blog in working context. Start with the biogenesis explainer, or skip ahead to the MISEV2023 pillar. MISEV2023 pillar EV biogenesis explainer ============================================================================== # For Dermatology Clinics — evaluation & procurement Source: https://biotherasolutions.com/resources/for-clinicians ============================================================================== Resources / For Clinicians For Dermatology Clinics # EV Supply for Dermatology Clinics How to evaluate an exosome skincare product for your clinic, and how to order plant-derived EV serum that meets a defensible standard. Batch-specific Certificate of Analysis, MISEV2023-aligned characterization, cold-chain shipping. Direct supply across Canada; early-access waitlist for US clinics. Request CoA & pricing Read the evaluation guide Clinician evaluation framework ## How to evaluate an exosome skincare product for your clinic Five criteria separate a characterized EV preparation from a label that uses the word "exosome" without backing it. None are optional. A defensible product answers all five. - 01 ### Source and biogenesis Confirm the EV source — plant, mammalian stem cell, platelet, or other — and that biogenesis (not just size) was demonstrated. Marker panel must include EV-associated proteins (CD9, CD63, CD81, TSG101, Alix where applicable) and the absence of contaminants. - 02 ### Particle concentration Concentration must be reported per mL on a batch-specific basis, measured by an orthogonal method (Nanoparticle Tracking Analysis is the field standard). Claims without a measured value belong in marketing copy, not a Certificate of Analysis. - 03 ### Certificate of Analysis Every shipment ships with a batch-specific CoA covering particle concentration, characterization method, marker panel, and contamination screen. Generic product sheets are not CoAs. - 04 ### Isolation method and the biomolecular corona Isolation method changes what is in the vial. Harsh methods strip the biomolecular corona; gentler methods preserve it. The corona is part of the active ingredient. Ask which isolation route the manufacturer uses and why. - 05 ### Cold-chain integrity EV preparations are biologically active and temperature-sensitive. Verify cold-chain handling from manufacturer to clinic, including transit excursion logging where the formulation requires it. The long-form version of this framework, with source literature and worked examples, lives at How to evaluate an EV or exosome product before stocking it . Procurement workflow ## How to order plant-derived EVs for your clinic Direct from BioThera's Ottawa facility to verified Canadian dermatology and aesthetic medicine practices. No distributor layer. Each shipment ships with its batch-specific Certificate of Analysis. Step 1 ### Verify credentials BioThera supplies plant-derived EVs directly to verified dermatology and aesthetic medicine practices, under our dermocosmetic brand, Vesera™. Submit your clinic credentials (regulatory license number, ordering physician, shipping address) through the contact form. Step 2 ### Request a batch-specific CoA Receive the active batch CoA before ordering. The CoA reports NTA particle concentration, EV marker panel, contamination screen, and MISEV2023 characterization disclosures. Step 3 ### Confirm cold-chain logistics Shipments leave Ottawa with cold-chain packaging suited to the destination. Confirm delivery windows, signature-on-receipt requirements, and storage conditions on intake. Step 4 ### Place your initial order Initial orders are sized to a single treatment cycle. Repeat orders run on a clinic-specific cadence agreed with the BioThera team. Pricing is disclosed to verified clinics; volume discounts apply. Cold-chain logistics ## Shipping across North America Origin ### Ottawa, Ontario Shipped directly from the BioThera Solutions facility. No distributor handoff . Transit ### 1–3 business days Canada-wide; 3–6 business days cross-border to US clinics post-launch Cold-chain packaging sized to the destination. Signature on receipt available on request. Quality ### Batch-specific CoA Every shipment includes the Certificate of Analysis for the batch in the box. MISEV2023 disclosures available on request. Direct supply — Canada ## Ships across Canada Health Canada-notified cosmetic. Cold-chain coverage to verified dermatology and aesthetic medicine clinics in every province. Direct supply ### Clinic supply in Toronto Toronto, Ontario — transit 1–2 business days from Ottawa . Direct supply ### Clinic supply in Montreal Montréal, Québec — transit 1 business day from Ottawa . Direct supply ### Clinic supply in Vancouver Vancouver, British Columbia — transit 2–3 business days from Ottawa . Early-access waitlist — United States ## Pre-launch in the US FDA / MoCRA cosmetic facility registration and product listing in progress. The waitlist reserves supply for verified dermatology, aesthetic medicine, and medspa partners at launch. Waitlist ### Clinic supply in New York New York, NY Waitlist ### Clinic supply in Los Angeles Los Angeles, CA Waitlist ### Clinic supply in Miami Miami, FL Waitlist ### Clinic supply in Chicago Chicago, IL FS Frédéric St-Denis-Bissonnette , PhD Founder & CEO, BioThera Solutions . Named contributor, MISEV2023. The evaluation framework on this page is the same one used inside BioThera's own characterization workflow. It is published openly so that clinicians can hold every EV product — including ours — to the same standard. Ready to order ## Request a Certificate of Analysis Clinics receive the active batch CoA before ordering. Pricing is disclosed to verified clinics. Contact the team See the applications ============================================================================== # FAQ Source: https://biotherasolutions.com/faq ============================================================================== BioThera Solutions, EV Science # Your Questions About EVs and Exosomes, Answered Directly. Everything you need to know about extracellular vesicles (EVs/exosomes), the Vesera™ Serum, and BioThera Solutions, without the marketing language. Answers are grounded in MISEV2023 standards and peer-reviewed literature. Categories About EVs & Exosomes 7 questions ### What are extracellular vesicles (EVs/exosomes)? Extracellular vesicles are nanoscale particles secreted by virtually every cell type. Each particle is a membrane-bound sphere built around a lipid bilayer, carrying a cargo of proteins, lipids, and nucleic acids that can influence gene expression and signalling in recipient cells. The field recognizes three subpopulations distinguished by biogenesis: apoptotic bodies, microvesicles (ectosomes), and exosomes from the multivesicular body pathway. The diagram below illustrates these three biogenesis routes from a single cell. "Exosome" is widely used in marketing as a synonym for EV, but technically refers only to particles produced through the multivesicular body pathway, which most commercial isolation methods cannot cleanly separate from other subpopulations. The International Society for Extracellular Vesicles (ISEV) recommends "extracellular vesicle" as the primary scientific term unless biogenesis has been experimentally confirmed. For the long-form treatment, see the blog article at /blog/ev-biogenesis-explained. Three EV subpopulations released by a single cell, distinguished by their biogenesis route. Sizes are illustrative; size alone is not sufficient to call a particle an exosome, biogenesis must be demonstrated through EV-associated protein markers and characterization data. ### Are all EV/exosome products the same? No, and this is the most critical thing to understand about the EV space. There is no such thing as a generic exosome product. Every EV preparation is unique, and its biological properties are entirely determined by: (1) the biological source, which cell type, tissue, organism, or plant species the EVs were isolated from; (2) the isolation method used; and (3) the processing and storage conditions applied. EVs from human stem cells, platelet-rich plasma, adipose tissue, and plant cells are all called "EVs" or "exosomes", but they carry completely different molecular payloads and have fundamentally different biological effects. This applies even across different suppliers claiming the same source: without standardized production and rigorous characterization, no two EV products can be assumed equivalent. The absence of industry-wide standardization means "exosome product" is a category, not a specification. ### Do EVs from different sources have different biological properties? Yes, substantially so. The molecular payload of an EV is a direct reflection of the cell or organism that produced it. EVs from different cell types (e.g., fibroblasts vs. immune cells), different tissues (e.g., bone marrow vs. adipose), and different biological kingdoms (e.g., human vs. plant) carry entirely distinct protein profiles, RNA species, lipid compositions, and surface markers. These differences translate directly into different biological effects on recipient cells. This is not a minor technical nuance, it is the central reason why EV products cannot be compared without knowing the source and characterization data. A product made from human platelet-derived EVs is biologically incomparable to one made from plant nanovesicles, even if both are marketed under the same "exosome" label. ### Why are EVs gaining attention in dermatology and regenerative medicine? EVs represent a natural biological communication system, they are how cells transfer functional molecular information to one another. In dermatology, EVs show potential to support skin repair, modulate inflammation, promote regenerative signalling, and activate pathways involved in collagen synthesis and barrier function. Unlike synthetic cosmetic ingredients, EVs participate in cell-level biological signalling through mechanisms the body already uses. In medicine more broadly, EVs are being investigated as therapeutic agents and drug delivery vehicles. The evidence base is growing rapidly, though clinical validation remains an active and evolving area of research. ### Can extracellular vesicles actually support skin regeneration? Peer-reviewed research supports the role of EVs in activating pathways associated with skin regeneration, including collagen synthesis, keratinocyte migration, extracellular matrix remodelling, and attenuation of inflammatory signalling. These are the same pathways targeted by leading medical-grade anti-aging interventions. The Vesera™ Serum delivers a characterized payload of antioxidant, anti-inflammatory, and regenerative signalling molecules at a verified concentration of 30 billion particles per mL, and it is currently in active dermatologist-led clinical evaluation under Health Canada's cosmetic regulatory framework. ### Why are plant-derived EVs used in skincare? Plant-derived EVs are BioThera's current commercial entry point for three substantiated reasons. (1) Scalability and cost-efficiency: botanical biomass is a renewable, high-yield EV source that supports consistent large-scale production without the ethical or logistical constraints of human- or animal-derived material. (2) Bioactive cargo relevance: plant-derived EVs carry confirmed payloads of antioxidant compounds, anti-inflammatory signalling molecules, and growth factor-associated proteins, as verified in BioThera's proteomics characterization data. (3) Regulatory and ethical simplicity: plant-derived sourcing avoids the complex donor screening, biosafety testing, and ethical review requirements that accompany human biological material. BioThera's platform is designed to span all EV modalities over time; plant-derived EVs represent a strategically sound, scientifically defensible starting point, not a ceiling. ### How do plant-derived EVs interact with the skin? How plant-derived EVs interact with skin is currently a topic of investigation, and BioThera's position reflects the current evidence base honestly rather than overstating it. The skin's outermost layer, the stratum corneum, is a tightly organized lipid-rich barrier, and the question of how nanoparticles in the size range of intact EVs traverse or interact with that barrier under realistic topical conditions is an active area of research across the EV field. The pathways under study include surface and superficial epidermal interactions, where EVs deliver their bioactive cargo to cells in the upper skin layers, and a follicular route via hair follicles and sebaceous glands. We do not claim deep dermal penetration of intact vesicles. The biological signalling effects supported by the research literature are driven by the bioactive payload EVs deliver at the skin interface, and our focus is on characterizing that payload and generating clinical evaluation data with dermatology partners. This framing is consistent with how the same topic is presented on our Technology page. Vesera™ — our dermocosmetic brand 9 questions ### What is the Vesera™ Serum? The Vesera™ Serum is BioThera Solutions' first commercial product, a dermocosmetic serum formulated with medicinal plant-derived extracellular vesicles. It is manufactured to a guaranteed minimum of 30 billion particles per millilitre and supplied in a 6.75 mL tube. The product is fully characterized: particle size distribution, concentration (verified by NTA), source, and bioactive payload are all documented per batch. ### What is the source of the EVs in the Vesera™ Serum? The EVs in the Vesera™ Serum are isolated from medicinal plant sources (botanical biomass), a deliberately chosen starting point that is cost-effective, sustainable, and ethically straightforward. Plant-derived EVs carry biologically relevant cargo confirmed by proteomics: antioxidant-active molecules and compounds associated with skin-soothing and conditioning properties. No animal testing occurs at any stage of Vesera™ Serum production. ### What bioactive cargo does the Vesera™ Serum contain? BioThera has identified three distinct bioactive payload classes in our plant-derived EVs, confirmed by proteomics. (1) Antioxidant fraction: plant-derived phenolic compounds and free radical scavengers associated with antioxidant activity in skin cell populations. (2) Skin-soothing fraction: signalling molecules studied in cell-based research for their association with calming and conditioning properties. (3) Skin-renewal fraction: growth factor-associated molecules and miRNA species studied in cell-based research for their role in supporting skin cell renewal. ### What is the particle concentration and how is it verified? The Vesera™ Serum is guaranteed at a minimum of 30 billion particles per millilitre (30 × 10⁹ particles/mL) per 6.75 mL tube. This is verified by Nanoparticle Tracking Analysis (NTA), the gold-standard method for EV characterization, and supported by a batch-specific Certificate of Analysis. Particle concentration is one of the most critical quality benchmarks for any EV product, and one that many brands in the market do not disclose. ### Is the Vesera™ Serum cruelty-free? Yes. The Vesera™ Serum holds active Leaping Bunny Cruelty-Free Certification. The current production chain is entirely plant-derived, with no animal testing at any stage. BioThera is committed to maintaining cruelty-free standards across all current and future product lines as the platform expands. ### Is the Vesera™ Serum approved by Health Canada, and how does BioThera ensure regulatory compliance and product safety? The Vesera™ Serum is registered with Health Canada under the Cosmetic Notification process, the required regulatory pathway for cosmetic products sold in Canada. Notification is complete and current, and the product falls under Health Canada's Cosmetic Regulations. On the safety side, every production batch undergoes a full quality panel including sterility testing, endotoxin screening, and viability markers, all documented in a batch-specific Certificate of Analysis. Our manufacturing protocols are informed by MISEV2023 characterization standards, which substantially exceed what is required for most cosmetic products. BioThera's standard is not the regulatory minimum, it is scientific credibility. ### When will the Vesera™ Serum be broadly available? The Vesera™ Serum is currently in an active research phase. We are working with selected dermatology partners to build the clinical evidence base the product deserves before broader deployment. Clinicians and interested parties can join our waitlist to be notified when access opens. ### Are plant-derived EVs regulated differently from synthetic cosmetic ingredients? In Canada, plant-derived EVs used as cosmetic ingredients are regulated under Health Canada's Cosmetic Regulations, the same framework that governs all cosmetic actives. There is no EV-specific regulatory category in Canada at this time. The Vesera™ Serum is registered via Health Canada's Cosmetic Notification process and operates within this cosmetic product category. What distinguishes BioThera's approach is that our manufacturing and characterization standards are held to a substantially higher level of rigour than most cosmetic products require, informed by pharmaceutical-grade quality thinking and MISEV2023 scientific standards. ### Where do I buy Vesera™? Vesera™ is supplied directly by BioThera to dermatology and medical-aesthetic clinics in Canada. Clinics should start with the clinician resources page, which covers the batch-specific Certificate of Analysis, cold-chain logistics and the ordering workflow. A dedicated Vesera™ storefront is planned; until it opens, join the early-access list on our applications page and we will notify you when access opens in your region. Science & Characterization 6 questions ### What is MISEV2023 and why does it matter? MISEV2023 (Minimal Information for Studies of Extracellular Vesicles) is the global scientific consensus standard published by the International Society for Extracellular Vesicles (ISEV). It defines the minimum characterization data required to credibly report an EV preparation: particle size distribution, concentration, EV-associated protein markers, and absence of contaminants, among other parameters. MISEV2023 matters because without it, no two EV studies or products can be meaningfully compared, it is the shared scientific language the field needs to mature. BioThera's characterization protocols are aligned with MISEV2023. Notably, BioThera's CEO is a named contributor to the MISEV2023 guidelines development process. ### Why does isolation method affect EV product quality? The method used to isolate EVs from a biological source fundamentally shapes the final preparation, including its purity, size distribution, surface protein composition, and biological activity. Ultracentrifugation, ultrafiltration, size exclusion chromatography (SEC), and precipitation-based methods all yield preparations with different characteristics, even from the same starting material. BioThera's scientific team has published peer-reviewed research demonstrating how isolation method alters the EV biomolecular corona, the layer of proteins and molecules on the EV surface that mediates its biological interactions with recipient cells. Process transparency is therefore not optional for any credible EV product. ### What is Nanoparticle Tracking Analysis (NTA)? NTA is the gold-standard technique for EV characterization. It tracks the Brownian motion of individual nanoparticles in liquid suspension under a laser, providing particle-by-particle size distribution and concentration data, not population averages. NTA is required by MISEV2023 for rigorous EV characterization and is how BioThera verifies the guaranteed 30 billion particles/mL specification in every batch of the Vesera™ Serum. ### Why is batch-to-batch consistency so difficult to achieve in EV manufacturing? Even minor variations in source material, harvest timing, isolation method, processing conditions, or storage can produce EV preparations with meaningfully different biological properties. This is because EVs are not a defined chemical compound, they are a population of biological particles whose composition reflects the dynamic state of the cells that produced them. Most EV preparations in both research and commercial settings show significant lot-to-lot variability, making it difficult to dose reliably or predict efficacy across batches. Addressing this variability through defined process controls and analytical verification at every production run is the core manufacturing challenge BioThera was built to solve. ### How does BioThera verify EV concentration and purity in every batch? Every production batch of the Vesera™ Serum is verified using Nanoparticle Tracking Analysis (NTA), the gold-standard characterization method under MISEV2023, to confirm a minimum of 30 billion particles per millilitre. Purity is assessed using the particle-to-protein ratio: a high ratio indicates a preparation enriched for EVs rather than contaminating protein aggregates or non-vesicular material. Results are documented in a batch-specific Certificate of Analysis. This is the verification standard BioThera applies to every batch, not just representative lots. In a market where most EV brands do not disclose concentration data at all, routine batch verification is the foundation of manufacturing accountability. ### What isolation method does BioThera use to produce the Vesera™ Serum? BioThera's EV isolation process is proprietary, with ongoing IP protection. The method has been chosen by our scientific team because, in our assessment, it is among the most scalable approaches available for plant-derived EV isolation, and because it relies on gentle processing steps that avoid mechanical or chemical damage to the vesicles during purification. Isolation method matters because it fundamentally shapes the final EV preparation: two preparations from the same source isolated by different methods will have different purity profiles, size distributions, surface protein compositions, and biological activities. BioThera's scientific team has published peer-reviewed research demonstrating how isolation method alters the EV biomolecular corona, the layer of proteins and molecules on the EV surface that mediates its biological interactions. For qualified manufacturing partners and clinical researchers, process transparency documentation is available upon request and disclosed under appropriate agreement. For Clinicians 6 questions ### What should I look for when evaluating any EV/exosome product? Five criteria every clinician should apply before stocking an EV product. (1) Source: what cell type, tissue, or organism are the EVs derived from? This determines their biological properties and makes products non-interchangeable. (2) Particle concentration: is there a verified particles/mL figure backed by NTA data? (3) Certificate of Analysis: is batch-specific documentation available? (4) Isolation method: is the process disclosed? Method directly affects product composition and quality. (5) Cold-chain integrity: EVs are thermolabile and must be handled and shipped under controlled temperature conditions. Our free EV SELECT GUIDE walks through each criterion in detail. ### Can I assume two EV products are equivalent if they're both called "exosomes"? No. "Exosome" describes a class of biological particles, not a standardized product. EVs from different sources, including different cell types, tissue origins, or biological kingdoms, have fundamentally different molecular payloads and mechanisms of action. This applies even across suppliers claiming the same source: without standardized production processes and equivalent characterization data, no two EV products can be scientifically assumed to be equivalent. The lack of industry-wide standardization is the defining regulatory and scientific challenge in this space. Evaluating each product on its own scientific merits, with data, is the only defensible clinical approach. ### How is BioThera different from other EV brands in the market? Many EV skincare brands cannot disclose particle concentration, do not provide batch-specific Certificates of Analysis, and use the term "exosome" without adequate characterization to support it. BioThera operates differently: scientifically rigorous characterization, guaranteed particle concentrations verified by NTA, batch-specific CoAs, Health Canada Cosmetic Notification, Leaping Bunny certification, and an active safety and efficacy study with practicing dermatologist partners. Our position is not against the cosmetics industry. It is that an elite cosmetic product should also meet the scientific standards of the EV science field, and we hold ourselves to both: the formulation, sensory, and regulatory standards expected of a premium cosmetic, and the characterization, transparency, and reproducibility standards expected of credible EV science. ### Can I request a Certificate of Analysis for the Vesera™ Serum? Yes. BioThera provides batch-specific Certificates of Analysis for the Vesera™ Serum upon request, including particle size distribution, NTA-verified concentration, and relevant characterization data. Submit a request through our contact page at biotherasolutions.com/contact. ### How does the Vesera™ Serum compare to other premium anti-aging serums? The Vesera™ Serum belongs to a different category than conventional skincare serums. Most premium skincare products, including leading peptide, retinoid, and vitamin C formulations, rely on synthetic active ingredients that work at the surface chemistry level. Plant-derived EVs operate through a fundamentally different mechanism: biological nanoparticles carrying characterized bioactive cargo that interact with skin cells. What distinguishes the Vesera™ Serum from other EV/exosome products on the market is manufacturing accountability: verified particle concentrations (30 billion particles per mL by NTA), rigorous batch-specific characterization, Certificates of Analysis, and an active safety and efficacy study with practicing dermatologist partners. In a category where many brands cannot substantiate their particle counts, this level of scientific transparency is the clinical-grade differentiator. ### What should a credible EV Certificate of Analysis include? A credible EV Certificate of Analysis (CoA) should document at minimum: (1) NTA-verified particle concentration with a stated particles/mL figure, not a range or estimate; (2) particle size distribution, including mean and mode diameter, confirming EV-range particles are the dominant population; (3) purity indicators such as particle-to-protein ratio, confirming the preparation is enriched for vesicles rather than co-isolated protein aggregates; (4) safety panel, including sterility testing and endotoxin/LPS screening to confirm the preparation is safe for topical application; and (5) source and batch traceability, identifying which source material, isolation run, and production date the data corresponds to. Certificates that list only a particle count without methodology, or that apply to a "representative lot" rather than the specific batch, should be treated with caution. BioThera provides batch-specific CoAs to qualified clinical partners, see the EV SELECT GUIDE for a full evaluation framework. About BioThera 6 questions ### What does BioThera Solutions do? BioThera Solutions is an Ottawa-based biomanufacturing company. We are not a generic dermatology brand. We build scalable, standardized infrastructure for the manufacturing of plant-derived extracellular vesicles, focused on solving the production and quality bottlenecks that have held the EV skincare category back from credible commercial use. Our first commercial application is the Vesera™ Serum, a medicinal plant-derived EV dermocosmetic, which serves as our commercial and scientific validation platform while we conduct the clinical research needed to build a credible evidence base. The longer-term vision is to scale that platform into a broader portfolio of dermocosmetic and EV-based skincare applications. ### Where is BioThera Solutions located? BioThera Solutions is headquartered in Ottawa, Ontario, Canada. Our location provides proximity to Health Canada, a growing life sciences ecosystem, and the clinical and research collaborators central to our work. ### Is BioThera Solutions raising investment? Yes. BioThera Solutions is conducting a pre-seed/seed round. For details, please visit our Investors page. ### What are BioThera's long-term plans for the platform? BioThera is building the plant-derived EV biomanufacturing platform that the dermocosmetic and EV-based skincare category requires. The Vesera™ Serum is our commercial validation point. The longer-term plan is to scale the same manufacturing infrastructure, characterization rigour, and clinical evidence base into a broader portfolio of dermocosmetic and EV-based skincare applications — built to the standards dermatologists and regulators expect. Every application we bring forward sits on top of the platform, IP position, and clinical data we are establishing today. ### How does BioThera ensure its product claims are accurate and science-grounded? BioThera's product claims are grounded in characterization data, not marketing language. Our work is aligned with MISEV2023, the global scientific consensus standard for EV characterization, and the methods, data, and reasoning behind that alignment are documented openly on our Technology page. We do not extrapolate from the broader EV literature to claims about our specific product; every claim we make about the Vesera™ Serum is backed by the data we generate on it. Scientific transparency is the standard we hold ourselves to. ### Is the Vesera™ Serum a medical-grade or skin regeneration serum? The Vesera™ Serum is classified and sold as a cosmetic product under Health Canada's Cosmetic Regulations. What distinguishes it is manufacturing rigour: NTA-verified particle concentration, batch-specific Certificates of Analysis, and an active safety and efficacy study with practicing dermatologist partners. Its manufacturing standards substantially exceed what most cosmetic products require. Clinicians looking for an EV skincare product they can evaluate on actual data, document with a CoA, and stand behind scientifically will find the Vesera™ Serum is built to that standard. Still have questions? ## We welcome scientific dialogue. Whether you are a clinician or researcher, we are happy to go deeper on any topic, EV science, manufacturing, characterization standards, or the platform roadmap. ============================================================================== # Blog — EV biogenesis explained Source: https://biotherasolutions.com/blog/ev-biogenesis-explained ============================================================================== Resources / Blog EV Science # What extracellular vesicles actually are, and why “exosome” is the wrong word for most products EVs are not a category of skincare ingredient. They are a class of biological particles defined by how they are made. Three biogenesis routes, three subpopulations, and a vocabulary problem that has shaped the entire commercial market. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Extracellular vesicles are nanoscale particles secreted by virtually every cell type known to biology. Each particle is a small, membrane-bound sphere built around a lipid bilayer, the same kind of membrane that surrounds the cell that released it. Inside that membrane, EVs carry a cargo of proteins, lipids, nucleic acids (including miRNA and mRNA), and other bioactive molecules. When taken up by recipient cells, this cargo can influence gene expression, modulate inflammatory signalling, and support repair and regeneration processes. EVs are how cells, across animals, plants, and microorganisms, transmit functional molecular information to one another. That single biological description hides a vocabulary problem the EV field has spent the last decade trying to clean up. The market uses "exosome" as if it were a synonym for EV. The science does not. ## Three subpopulations, three biogenesis routes The International Society for Extracellular Vesicles (ISEV) defines three principal EV subpopulations, distinguished not by size but by the cellular machinery that produces them. Apoptotic bodies are released as cells break down at the end of their life cycle, through a process of membrane blebbing during programmed cell death. They are typically the largest of the three, ranging from roughly 1,000 to 5,000 nm. Microvesicles , also called ectosomes, form by direct outward budding of the plasma membrane and pinch off into the extracellular space. They span an intermediate size range, roughly 100 to 1,000 nm. Exosomes are produced through a more elaborate intracellular pathway. The process begins inside the cell with the formation of multivesicular bodies (MVBs), which are endosomal compartments that gather small vesicles internally through inward budding. When an MVB fuses with the plasma membrane, those internal vesicles are released to the extracellular space as exosomes. They are typically the smallest of the three, roughly 30 to 150 nm. Three EV subpopulations released by a single cell, distinguished by their biogenesis route. Sizes are illustrative; size alone is not sufficient to call a particle an exosome, biogenesis must be demonstrated through EV-associated protein markers and characterization data. Three EV subpopulations released by a single cell, distinguished by their biogenesis route. Sizes are illustrative; size alone is not sufficient to identify a particle as an exosome. Biogenesis must be demonstrated through EV-associated protein markers and characterization data. ## Why "exosome" almost always means something else The term "exosome" is technically reserved for particles produced by the multivesicular body pathway. To call a preparation an exosome credibly, you have to demonstrate that biogenesis route. The standard evidence is a combination of EV-associated protein markers, including CD9, CD63, CD81, TSG101, and Alix, that confirm MVB origin, alongside data showing the absence of contaminating non-vesicular material. Most current isolation techniques cannot cleanly separate exosomes from the other two subpopulations. They produce mixed EV preparations, with exosomes, microvesicles, and a smaller fraction of apoptotic bodies all present in the same suspension. That is the technical reality MISEV2023 was written to address: when biogenesis cannot be experimentally confirmed, the correct term is "extracellular vesicle", not "exosome." Almost no commercial product on the market today provides marker-confirmed biogenesis data for what it sells as exosomes. The label is a shorthand the market adopted because "EV" did not test well in consumer research. The science kept the precise term and added the umbrella one. The market kept the wrong term and dropped the precise one. ## What this means for clinicians and partners Three things follow from the biology. First, two products marketed as exosomes are not assumed equivalent without source, isolation, and characterization data. Source determines what cargo the EV carries. Isolation method determines which subpopulations dominate the final suspension and how much non-vesicular material rides along. Characterization data determines whether the count on the label corresponds to actual EV-range particles or to a broader nanoparticle population. Second, particle concentration on a Certificate of Analysis is meaningful only when the analytical method is named. Nanoparticle Tracking Analysis (NTA) is the gold standard under MISEV2023. A "particle count" produced by another method, or no method at all, does not carry the same evidentiary weight. Third, the precise term to use in formal scientific or clinical writing is "extracellular vesicle" or "EV." In product copy aimed at clinicians and consumers, the working compromise is "EV/exosome" together, which is what we use across BioThera communications. It bridges scientific precision with the language already in use without privileging the marketing convention over the science. ## The downstream consequence Every comparison clinicians and procurement teams make about EV products downstream of this point depends on the vocabulary being right at the start. Source, biogenesis, isolation, characterization. If those four are not specified, "exosome product" is a category claim, not a specification. The work of the EV field over the past five years has been to make the specification possible. The work of credible EV manufacturers is to publish it. References ## Primary sources - Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, St-Denis-Bissonnette F, et al. . Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - Théry C, Witwer KW, Aikawa E, et al. . Minimal information for studies of extracellular vesicles 2018 (MISEV2018) . Journal of Extracellular Vesicles , 2018 . doi.org/ 10.1080/20013078.2018.1535750 - van Niel G, D’Angelo G, Raposo G. . Shedding light on the cell biology of extracellular vesicles . Nature Reviews Molecular Cell Biology , 2018 . doi.org/ 10.1038/nrm.2017.125 Related reading ## Continue exploring EV Science ### Plant-derived versus mammalian extracellular vesicles, compared honestly Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map. EV Science ### Cross-kingdom EV signalling: what the evidence supports, and what it does not Plant-derived EVs are taken up by mammalian cells. Their cargo can modulate gene expression in preclinical models. Clinical translation in human skin is where the evidence base is still maturing. Reading the literature requires holding both at once. EV Science ### The biomolecular corona, and why isolation method changes what an EV product actually is Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Blog — Plant-derived vs mammalian EVs Source: https://biotherasolutions.com/blog/plant-derived-vs-mammalian-evs ============================================================================== Resources / Blog EV Science # Plant-derived versus mammalian extracellular vesicles, compared honestly Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Plant-derived EVs (PDEVs) and mammalian EVs share the same fundamental structure. Both are nanoscale particles bounded by a lipid bilayer membrane that encloses a cargo of proteins, nucleic acids, and signalling lipids. From the level of basic particle architecture, the two modalities are siblings. From the level of biology, manufacturing, and clinical evidence, they belong in different conversations. Treating "EV" as a single commercial category obscures the differences that actually matter. ## Biological origin and cargo Mammalian EVs are produced inside evolutionarily conserved signalling systems. Their surface proteins, including the tetraspanin family (CD9, CD63, CD81), engage cognate receptors on human target cells with high biological precision. Cargo molecules carried by mammalian EVs, including growth factors, cytokines, and regulatory RNAs, were shaped by the same selection pressures that produced the human cell receptors they act on. Plant-derived EVs carry plant-specific cargo. The signalling proteins, regulatory miRNAs, and lipid species are products of plant biology, not mammalian. What the cross-kingdom literature has established over the past decade is that several functional categories of that cargo, including antioxidant enzymes, heat shock proteins, signalling lipids, and certain RNA species, retain biological activity in mammalian cells under preclinical conditions. The mechanism is not that plant proteins map perfectly to human receptors. The mechanism is that plants evolved bioactive molecules of broad chemical and structural utility, many of which have downstream effects in human cells that are now well characterized. ## Safety profile Mammalian EVs from allogeneic sources require rigorous donor screening for transmissible pathogens, viral contamination, and cellular impurities. Donor variability is a real and unresolved manufacturing constraint. Even autologous mammalian EV preparations require quality testing on every collection. Plant-derived EVs carry no risk of transmitting human pathogens. Botanical biomass does not host the viruses, prions, or human cellular components that drive most safety screening for mammalian EV manufacturing. There is no donor variability because there is no donor. For cosmetic topical use, this gives plant-derived EVs a clear and uncontroversial safety profile advantage. ## Manufacturing and scalability Mammalian EV production requires GMP-grade cell culture, validated cell banking, and tightly controlled bioreactor systems. The cell line itself is part of the regulated raw material. The economics scale poorly. A clinical-grade mammalian EV manufacturing run can consume hundreds of litres of cell culture media to produce a kilogram-scale order of EV-active material. Plant-derived EVs are isolated from botanical biomass. The biomass is renewable, agriculturally scalable, and orders of magnitude cheaper than mammalian cell culture per unit of EV yield. The unit economics work at commercial scale in a way that mammalian EV production does not, at least not yet. This is the primary reason plant-derived EVs are the rational entry point for a commercially viable EV dermocosmetic. ## Scientific evidence base Mammalian EVs, especially mesenchymal stem cell-derived (MSC-EV) preparations, have a substantially deeper clinical literature. Wound healing, inflammatory disease, and certain neurology applications are the areas with the most published evidence. Multiple early-phase trials are active. Plant-derived EV research has a younger but rapidly growing literature. The cross-kingdom signalling work, the cargo characterization work, and the topical bioavailability work are well represented in peer-reviewed journals. The clinical literature for cosmetic applications is earlier in development. Honest framing of the field requires holding both: there is enough preclinical evidence to support topical cosmetic positioning of well-characterized plant-derived EVs, and there is not yet enough clinical evidence to make therapeutic-grade claims that mammalian MSC-EVs can defensibly make. MISEV2023 characterization standards apply to both. NTA-verified particle counts, size distribution, EV-associated protein markers, and absence of contaminants are required for any credibly characterized EV preparation, regardless of source. ## Regulatory position For cosmetic use, both plant-derived and mammalian EVs are regulated as cosmetic ingredients in most jurisdictions. The substantive regulatory difference shows up at the therapeutic end of the spectrum. Mammalian EV therapeutic products face complex cell-therapy-adjacent regulatory pathways under FDA, EMA, and Health Canada therapeutic frameworks. Plant-derived EVs, when used in cosmetic applications, operate within comparatively simpler botanical-ingredient regulatory frameworks that are a closer analogue to other plant-derived cosmetic actives. BioThera's Vesera™ Serum is registered with Health Canada under the Cosmetic Notification process. It is classified as a cosmetic, characterized to standards substantially exceeding what cosmetic regulation requires. ## Practical positioning Mammalian EVs carry the deeper clinical evidence base for therapeutic applications and are likely to remain the dominant modality for clinically administered EV interventions in regenerative medicine and oncology. Plant-derived EVs offer a more scalable manufacturing base, an established safety profile for cosmetic use, and sufficient preclinical evidence to support topical cosmetic positioning. They are not the same product class. They are not competing for the same use cases. The clean version of the comparison treats them as two adjacent modalities with overlapping biophysical properties and divergent commercial roles. That framing is the foundation of how BioThera positions its commercial roadmap. Plant-derived EVs are the entry point, not the ceiling. The platform is being built to span both. References ## Primary sources - Mu J, Zhuang X, Wang Q, et al. . Interspecies communication between plant and mouse gut host cells through edible plant-derived exosome-like nanoparticles . Molecular Nutrition & Food Research , 2014 . doi.org/ 10.1002/mnfr.201300729 - Welsh JA, et al. (incl. St-Denis-Bissonnette F) . Minimal information for studies of extracellular vesicles (MISEV2023) . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - Lener T, Gimona M, Aigner L, et al. . Applying extracellular vesicles based therapeutics in clinical trials, an ISEV position paper . Journal of Extracellular Vesicles , 2015 . doi.org/ 10.3402/jev.v4.30087 - Kim J, Li S, Zhang S, Wang J. . Plant-derived exosome-like nanoparticles and their therapeutic activities . Asian Journal of Pharmaceutical Sciences , 2022 . doi.org/ 10.1016/j.ajps.2021.05.006 Related reading ## Continue exploring EV Science ### Cross-kingdom EV signalling: what the evidence supports, and what it does not Plant-derived EVs are taken up by mammalian cells. Their cargo can modulate gene expression in preclinical models. Clinical translation in human skin is where the evidence base is still maturing. Reading the literature requires holding both at once. EV Science ### Aloe barbadensis-derived extracellular vesicles in dermocosmetic formulation Aloe vera has a 3,000-year cosmetic history. The nanovesicles inside aloe leaf parenchyma are a more recent finding. Their cargo, their stability, and their suitability as a scalable dermocosmetic active deserve separate treatment from the broader plant-EV literature. For Clinicians ### How to evaluate an EV or exosome product before stocking it Five criteria: source, particle concentration, Certificate of Analysis, isolation method, cold chain. None are optional. Each one separates a characterized EV preparation from a label that uses the word "exosome" without backing it. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Blog — Cross-kingdom EV signalling Source: https://biotherasolutions.com/blog/cross-kingdom-ev-signalling ============================================================================== Resources / Blog EV Science # Cross-kingdom EV signalling: what the evidence supports, and what it does not Plant-derived EVs are taken up by mammalian cells. Their cargo can modulate gene expression in preclinical models. Clinical translation in human skin is where the evidence base is still maturing. Reading the literature requires holding both at once. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Cross-kingdom EV communication has been documented in the peer-reviewed literature since the early 2010s. The basic finding is reproducible across multiple plant sources, multiple research groups, and multiple in vivo and in vitro experimental systems: nanoparticles isolated from plant biomass are taken up by mammalian cells through endocytic pathways, and at least a subset of their cargo reaches the intracellular space with measurable biological consequence. The interesting work is no longer establishing whether the phenomenon exists. It is in mapping its boundaries. Reading the literature carefully means separating three layers: what is supported by direct experimental evidence, what is supported by mechanistic plausibility, and what remains an open clinical question. ## What the evidence directly supports Plant-derived EVs from ginger, grapefruit, grape, broccoli, aloe vera, and other species have been shown to enter mammalian cells in vitro through macropinocytosis and clathrin-mediated endocytosis. Once internalized, plant-EV-encapsulated miRNAs have been detected inside recipient mammalian cells, with measurable effects on gene expression demonstrated in preclinical models. Anti-inflammatory, antioxidant, and proliferation-supporting effects have been documented for multiple plant EV sources, primarily in murine in vivo models of intestinal inflammation, oxidative skin stress, and wound healing. These are not isolated case studies. They are a consistent body of preclinical work, drawn from multiple plant sources and multiple model systems, with results published in peer-reviewed journals across more than a decade. The cross-kingdom EV literature is one of the more reproducible bodies of work in the broader plant-EV field. ## A note on the “not real exosomes” claim Some suppliers of human-cell-derived EV products make the public claim that plant-derived EV products are not "real" exosomes, do not communicate with human cells, or are biologically inert. This is not a position the published evidence supports. If plant-derived molecules could not interact with human biology, the entire pharmaceutical industry would not function. Thousands of clinically used drugs and active pharmaceutical ingredients, from morphine to artemisinin, taxol, salicylic acid, digoxin, paclitaxel, and metformin (its chemistry derived from a plant compound), are derived directly from plants. Plant-derived natural products are a foundational pillar of modern medicine. The technical question of whether a plant-derived EV preparation meets the strict MISEV2023 definition of an "exosome" (a particle of confirmed multivesicular-body biogenesis) is a separate matter, and one we treat with deliberate care in our own communications. We use "EV" or "EV/exosome" together rather than relying on "exosome" alone. The biology of cross-kingdom signalling does not require the strict-exosome definition to hold. ## What the evidence supports more conditionally The functional categories of bioactive cargo in plant-derived EVs, including bioactive lipids, antioxidant proteins, and select RNA species, modulate cellular responses in preclinical mammalian systems. Anti-inflammatory and antioxidant effects are the best-supported functional categories. Effects on proliferation, migration, and barrier-supporting pathways have been documented in skin-relevant cell culture models. These functional categories align directly with the proteomics-confirmed payload of BioThera's Vesera™ preparation. We do not reason from the broader literature to claims about our specific product. We characterize our specific product, confirm the presence of bioactive protein classes the cross-kingdom literature supports as functionally active, and report the data on a per-batch Certificate of Analysis. ## What the evidence does not yet establish Two questions remain genuinely open and the field is honest about them. The first is the precise uptake mechanism operating under realistic topical delivery conditions in intact human skin. Most cross-kingdom EV uptake work has been done in cell culture, in murine in vivo models, or in oral / intestinal delivery contexts. Topical application onto an intact stratum corneum is a different barrier problem from intestinal uptake or systemic injection. The literature on EV interactions at the skin barrier is growing and includes credible work on follicular delivery and superficial epidermal interactions, but it is not yet at a level of resolution that supports specific deep-dermal mechanism claims for any plant-derived EV product. The second is the translation of preclinical signalling data into confirmed clinical outcomes at scale, in humans, for cosmetic skin endpoints. This is the gap every credible EV company is currently working to close. The honest position is that the preclinical evidence base supports topical cosmetic positioning of well-characterized plant-derived EVs, and that confirmed human clinical outcome data is what the next generation of dermatologist-led evaluation work has to produce. We are conducting that work. ## How BioThera communicates the science Our approach reflects this distinction precisely. We characterize the Vesera™ payload through MISEV2023-aligned methods and confirm the presence of bioactive protein classes supported by the cross-kingdom literature. Characterization tells us what we deliver. Clinical evaluation, currently active with dermatology partners, tells us what it does in human skin under controlled use conditions. Saying more than the evidence supports is the easiest way to lose the right kind of audience. Saying less than the evidence supports is how a defensible scientific position gets mistaken for a marketing-grade hedge. The line between the two is where every claim about a credible EV product has to sit. References ## Primary sources - Mu J, Zhuang X, Wang Q, et al. . Interspecies communication between plant and mouse gut host cells through edible plant-derived exosome-like nanoparticles . Molecular Nutrition & Food Research , 2014 . doi.org/ 10.1002/mnfr.201300729 - Zhang M, Viennois E, Prasad M, et al. . Edible ginger-derived nanoparticles, a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease . Biomaterials , 2016 . doi.org/ 10.1016/j.biomaterials.2016.06.018 - Ju S, Mu J, Dokland T, et al. . Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis . Molecular Therapy , 2013 . doi.org/ 10.1038/mt.2013.64 - Teng Y, Ren Y, Sayed M, et al. . Plant-derived exosomal microRNAs shape the gut microbiota . Cell Host & Microbe , 2018 . doi.org/ 10.1016/j.chom.2018.10.001 - Kim J, Li S, Zhang S, Wang J. . Plant-derived exosome-like nanoparticles and their therapeutic activities . Asian Journal of Pharmaceutical Sciences , 2022 . doi.org/ 10.1016/j.ajps.2021.05.006 Related reading ## Continue exploring EV Science ### Plant-derived versus mammalian extracellular vesicles, compared honestly Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map. EV Science ### Aloe barbadensis-derived extracellular vesicles in dermocosmetic formulation Aloe vera has a 3,000-year cosmetic history. The nanovesicles inside aloe leaf parenchyma are a more recent finding. Their cargo, their stability, and their suitability as a scalable dermocosmetic active deserve separate treatment from the broader plant-EV literature. EV Science ### The biomolecular corona, and why isolation method changes what an EV product actually is Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Blog — EVs vs PRP for skin applications Source: https://biotherasolutions.com/blog/evs-vs-prp-skin-applications ============================================================================== Resources / Blog For Clinicians # Extracellular vesicles versus PRP for skin applications PRP and EV preparations are both growth-factor-rich biological inputs that act through cellular signalling. They differ in origin, consistency, delivery, patient experience, and evidence maturity. Treating them as competitors misses the point. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Platelet-rich plasma and extracellular vesicle preparations both deliver biologically derived signalling molecules with relevance to skin health. Both work through pathways involved in tissue repair, growth factor signalling, and inflammation modulation. Beyond that shared layer, they are distinct categories with different practical properties. Choosing between them is a clinical decision shaped by the use case, the patient, the available evidence base, and the operational constraints of the practice. ## What PRP is, and where it sits today PRP is prepared from the patient's own blood, typically through a single-step or two-step centrifugation that concentrates platelets and the growth factors stored in their alpha granules, including PDGF, TGF-β, VEGF, EGF, and IGF-1. The clinical literature for PRP is mature in several specific domains. Wound healing, hair restoration, and certain aesthetic medicine applications have a body of randomized and observational evidence behind them. PRP remains the current clinical benchmark for biologically based skin regeneration procedures performed in the office setting. The technique has practical limitations that are clinically meaningful and well documented. Composition varies significantly between patients. Younger patients typically produce PRP with higher growth factor content and better in vitro performance than older patients drawn from the same protocol. The final preparation also varies depending on the technician performing the venipuncture and centrifugation, which adds operator-induced variability on top of the donor-induced variability. There is no universally standardized concentration protocol across providers, which makes cross-clinic outcome comparisons difficult. The procedure itself requires a venipuncture. That introduces a real patient-side cost: invasiveness, transient or persistent discomfort, the inherent risks of any blood draw (bruising, hematoma, vasovagal responses, rare infection), and biological activity that degrades rapidly after collection. None of these are deal-breakers for the clinical settings PRP is built for. They are constraints that shape where PRP fits. ## What characterized EV preparations offer A characterized EV preparation is a different modality, even though the active material is also a population of biological signalling particles. The key differences sit in three places. Reproducibility. A characterized EV preparation is manufactured to a specification, not drawn from each patient on the day of treatment. NTA-verified particle counts, proteomics-confirmed payload, batch-specific Certificate of Analysis. The active material is the same across patients within the same lot. There is no donor-level variability and no operator-level variability in the active itself. Delivery. Topical application is non-invasive. No venipuncture, no centrifugation, no procedural pain. The patient experience is closer to a serum application than to a clinical procedure. For practices that want to extend EV-class signalling beyond the in-office setting, this is an enabling difference. Storage and shelf life. Properly formulated EV preparations carry a shelf life under appropriate cold-chain handling that is meaningfully longer than the post-collection viability of PRP. The active does not have to be produced and used in the same hour. The current limitation, stated honestly, is that the clinical evidence base for cosmetic EV preparations, including plant-derived formulations, is earlier in development than PRP's. The mechanistic plausibility, the preclinical signal, the manufacturing standards: those are well established. Confirmed clinical outcome data at large scale across populations is the next chapter of the work, and it is the one credible EV manufacturers are currently writing. ## How they actually relate These are distinct rather than competing categories. PRP remains the evidence-backed choice for clinically administered regenerative procedures targeting structural outcomes, especially in wound healing, hair restoration, and tissue repair. EVs are positioned as a standardized, scalable, non-invasive approach delivering characterized biological signals, suited to topical cosmetic applications where reproducibility, safety profile, and patient accessibility are the dominant constraints. Many practices will end up using both, because they are not solving the same problem. PRP is well suited to in-office regenerative procedures with structural endpoints. A characterized EV serum is well suited to topical cosmetic protocols, post-procedure recovery, and at-home maintenance regimens that the practice prescribes alongside in-office work. ## What "characterized" actually means The comparison only holds if the EV preparation in question is genuinely characterized. An "exosome serum" with no disclosed particle count, no Certificate of Analysis, and no documented isolation method is not the same product class as a preparation with NTA-verified concentration, proteomics-confirmed cargo, and batch-specific CoAs. The rigour bar here matters. BioThera's Vesera™ Serum is designed for the characterized end of this spectrum: a topically delivered, proteomics-verified, NTA-confirmed preparation with an active dermatologist-led clinical evaluation program. The point of the EV-versus-PRP comparison is not to argue one against the other. It is to make the operational properties of each visible enough that a clinician can decide where each one fits in the practice. References ## Primary sources - Marx RE. . Platelet-rich plasma (PRP), what is PRP and what is not PRP . Implant Dentistry , 2001 . doi.org/ 10.1097/00008505-200110000-00002 - Alves R, Grimalt R. . A review of platelet-rich plasma: history, biology, mechanism of action, and classification . Skin Appendage Disorders , 2018 . doi.org/ 10.1159/000477353 - Welsh JA, et al. (incl. St-Denis-Bissonnette F) . Minimal information for studies of extracellular vesicles (MISEV2023) . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - Kim YJ, Yoo SM, Park HH, et al. . Extracellular vesicles from human umbilical cord mesenchymal stem cells stimulate cell proliferation and skin regeneration . Stem Cell Research & Therapy , 2017 . doi.org/ 10.1186/s13287-017-0622-2 Related reading ## Continue exploring For Clinicians ### How to evaluate an EV or exosome product before stocking it Five criteria: source, particle concentration, Certificate of Analysis, isolation method, cold chain. None are optional. Each one separates a characterized EV preparation from a label that uses the word "exosome" without backing it. For Clinicians ### Post-procedure EV protocols: what we can say, and what is still under evaluation Post-laser, post-microneedling, post-chemical peel: clinics are increasingly asking where EV serums fit. The honest answer requires separating mechanistic plausibility, preclinical signal, and confirmed clinical outcome. EV Science ### Plant-derived versus mammalian extracellular vesicles, compared honestly Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Blog — The biomolecular corona & EV products Source: https://biotherasolutions.com/blog/biomolecular-corona-ev-products ============================================================================== Resources / Blog EV Science # The biomolecular corona, and why isolation method changes what an EV product actually is Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Most published descriptions of EV products treat the vesicle as the active ingredient. The truth is more specific. The active ingredient is the vesicle and the layer of biomolecules adsorbed onto its surface. That outer layer, the biomolecular corona, mediates how the EV interacts with the recipient cell membrane. It is not an artefact. It is part of the particle, and it is shaped by the isolation method that produced the preparation. Two EV preparations isolated from identical biomass by different methods are not the same product. Anyone making purchasing decisions about EV-based actives should understand why. ## What the corona is When an EV is suspended in a biological fluid, proteins, lipids, glycans, and other small molecules from that fluid bind to its outer surface. Some bind tightly through specific high-affinity interactions, forming what is called the hard corona. Others bind through weaker electrostatic and hydrophobic interactions and form a more dynamic soft corona. Both layers contribute to the particle's identity from the perspective of recipient cells. The corona is functionally meaningful. It influences cellular uptake pathways, determines which receptors on the recipient cell are engaged, and shapes the downstream signalling response. A bare EV with the corona stripped off is biophysically the same particle. Biologically, it behaves differently. ## What isolation method does to it Our group's published work directly tested this: ultracentrifugation and ultrafiltration produce EV preparations from the same starting material that differ measurably in corona composition and functional activity downstream. The two methods do not just yield different particle yields. They yield particles with different surfaces. The mechanism is straightforward. Ultracentrifugation applies high gravitational force over long periods, which can shear the loose corona, fragment less stable EV subpopulations, and pellet contaminating non-vesicular protein aggregates that then co-isolate with the vesicles. Ultrafiltration uses a size-cutoff membrane and depends on different physical principles; it preserves more of the soft corona but can introduce adsorption losses to the membrane and concentration-dependent aggregation effects. Size exclusion chromatography (SEC) preserves the corona more gently than either, with its own trade-offs in yield and concentration. None of these methods are wrong. They produce different preparations. The question is whether the preparation that ends up in a commercial product was made with awareness of these trade-offs and characterized accordingly, or whether the corona was simply not on the manufacturer's radar. ## What this means for EV product evaluation Three implications follow. First, "EVs from species X" is not a complete specification of what the product is. Source biomass plus isolation method together determine the active particle. Two products marketed as "aloe-derived EVs" or "rose-stem-cell exosomes" or "ginger nanovesicles" may carry meaningfully different surface chemistry depending on how they were isolated, even when source is identical. Second, batch-to-batch consistency in an EV product depends on holding both source variability and processing variability inside narrow specifications. A manufacturer that has not characterized how their isolation method shapes the corona is, by definition, not controlling for one of the two main drivers of lot-to-lot variation. Third, isolation method should be disclosable to qualified clinical and manufacturing partners. Process secrecy is normal in the supplements industry, and it has no place in characterized EV manufacturing. The method is part of what the product is. BioThera's isolation process is proprietary, with ongoing IP protection, and process transparency documentation is available to qualified partners under appropriate agreement. The standard is "characterized and disclosed under terms," not "undisclosed by default." ## Why the field is moving on this The corona work is part of a broader maturation of the EV field. MISEV2023, the most recent global characterization standard, places explicit emphasis on documenting isolation method and on characterizing not just particle counts but particle properties relevant to function. The corona literature has grown from a handful of foundational studies in the 2010s to a recognized component of EV characterization at the preclinical and clinical levels. For clinicians and procurement teams: the right question is not "do you preserve the corona." Almost no manufacturer can answer that confidently if they have not done the work. The right question is the one MISEV2023 implies: "what is your isolation method, what does the resulting particle look like in your characterization data, and is that consistent across batches." The corona discussion sits inside that question. It is not a separate audit item. It is part of why the audit matters. References ## Primary sources - St-Denis-Bissonnette F, et al. . Ultracentrifugation and ultrafiltration differentially alter the composition and functionality of the biomolecular corona of extracellular vesicles . Journal of Extracellular Biology , 2026 . doi.org/ 10.1002/jex2.70132 - Tóth EÁ, Turiák L, Visnovitz T, et al. . Formation of a protein corona on the surface of extracellular vesicles in blood plasma . Journal of Extracellular Vesicles , 2021 . doi.org/ 10.1002/jev2.12140 - Heidarzadeh M, Zarebkohan A, Rahbarghazi R, Sokullu E. . Protein corona and exosomes: new challenges and prospects . Cell Communication and Signaling , 2023 . doi.org/ 10.1186/s12964-023-01089-1 - Welsh JA, et al. (incl. St-Denis-Bissonnette F) . Minimal information for studies of extracellular vesicles (MISEV2023) . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 Related reading ## Continue exploring EV Science ### What extracellular vesicles actually are, and why "exosome" is the wrong word for most products EVs are not a category of skincare ingredient. They are a class of biological particles defined by how they are made. Three biogenesis routes, three subpopulations, and a vocabulary problem that has shaped the entire commercial market. For Clinicians ### How to evaluate an EV or exosome product before stocking it Five criteria: source, particle concentration, Certificate of Analysis, isolation method, cold chain. None are optional. Each one separates a characterized EV preparation from a label that uses the word "exosome" without backing it. EV Science ### Plant-derived versus mammalian extracellular vesicles, compared honestly Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Blog — Evaluating EV/exosome products (clinician guide) Source: https://biotherasolutions.com/blog/evaluating-ev-products-clinician-guide ============================================================================== Resources / Blog For Clinicians # How to evaluate an EV or exosome product before stocking it Five criteria: source, particle concentration, Certificate of Analysis, isolation method, cold chain. None are optional. Each one separates a characterized EV preparation from a label that uses the word “exosome” without backing it. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions The EV skincare market grew faster than the standards needed to evaluate it. Clinics are increasingly asked to make procurement and prescribing decisions about products labelled "exosome" or "EV" with no shared scientific framework for separating substantiated products from labels. The criteria below are the five questions every clinician should ask before stocking an EV product. Each one is a specific data point. None of them are negotiable. These criteria are also the structure of BioThera's free EV SELECT GUIDE, which goes deeper on each one and includes a printable evaluation worksheet. The framework here is the short form. ## 1. Source What cell type, tissue, organism, or plant species are the EVs derived from? This is the first question because it determines almost everything else about the product. EVs from human stem cells, platelet-rich plasma, adipose tissue, plant cells, and microbial sources all carry different molecular cargo and act through different mechanisms. They are biologically incomparable. A product that does not name its source clearly, beyond a generic "exosome" label, has not given you the information you need. Look for the species, the tissue or biomass, and ideally the strain or cultivar. "Plant-derived" is not specific enough. "Aloe barbadensis leaf" is. The same applies to mammalian sources: "stem cell-derived" is not specific enough; "human umbilical cord mesenchymal stem cell" is. ## 2. Particle concentration Is there a verified particles-per-millilitre figure, and is the analytical method named? The gold standard for particle counting under MISEV2023 is Nanoparticle Tracking Analysis (NTA), which measures individual particles in suspension and reports both concentration and size distribution. A credible product specifies its particle count as an NTA-verified figure with a stated lower bound, on a per-batch basis, not as a marketing range or a "representative lot" figure. Products that do not disclose particle concentration at all should be considered uncharacterized. There is no way to dose them and no way to compare them to alternatives. The absence of this number is a signal, not a stylistic choice. ## 3. Certificate of Analysis Is batch-specific documentation available, or is the same CoA recycled across all production runs? A credible EV CoA documents at minimum: NTA-verified particle concentration with a stated particles/mL figure (not a range), particle size distribution including mean and mode diameter, purity indicators such as particle-to-protein ratio, a safety panel covering sterility and endotoxin / LPS screening, and source plus batch traceability identifying the production run the data corresponds to. The phrase to watch for is "representative lot." A representative-lot CoA is not a quality document. It is a sample of one batch held up as evidence about all batches, which is exactly the opposite of what batch verification means. BioThera issues batch-specific CoAs. Any credible manufacturer should. ## 4. Isolation method Is the production process disclosed, even at the level of which method family was used? Isolation method directly shapes the final EV preparation. Ultracentrifugation, ultrafiltration, size exclusion chromatography, and precipitation all yield preparations with different purity profiles, different size distributions, different surface protein compositions, and different biological activities. Two products from the same source isolated by different methods are not the same product. Not every manufacturer can disclose every detail of a proprietary process publicly, and that is reasonable. What is not reasonable is "we cannot tell you anything." A credible manufacturer can tell you the method family and provide process transparency documentation under appropriate agreement to qualified clinical and manufacturing partners. Process secrecy is a supplements-industry norm with no place in characterized EV manufacturing. ## 5. Cold chain EVs are thermolabile biological particles. They lose biological activity under elevated temperatures, freeze-thaw cycles outside specification, and prolonged storage at uncontrolled conditions. A credible EV product specifies storage temperature, ships under controlled-temperature conditions, and provides clear in-clinic and patient-side handling instructions. A product shipped at ambient temperature with no temperature monitoring is, at best, untested under realistic logistics. At worst, it is biologically degraded by the time it reaches the consultation room. For procurement teams, ask about temperature monitoring during shipment, recommended storage conditions, and shelf life under those conditions. The answers should be specific. ## What the framework rules out Apply the five criteria to a typical "exosome" cosmetic product on the market today and a clear pattern emerges. Source is often vague. Particle concentration is undisclosed or stated without methodology. CoAs are either absent or "representative." Isolation method is treated as a trade secret with no qualified-partner disclosure path. Cold chain is rarely specified. That is not a quality EV product. It is a label using EV vocabulary without the underlying characterization. The framework above is how clinicians draw that line. ## What it lets in A characterized EV preparation, by contrast, will answer all five questions specifically. Named source. NTA-verified particle count with a lower bound. Batch-specific CoA available. Isolation method disclosed at the family level with deeper transparency under partner agreement. Cold-chain protocol stated. That set of answers is what BioThera's Vesera™ Serum was built to deliver and what we expect any credible peer EV manufacturer to be able to match. The criteria are not a competitive advantage. They are a baseline. For the deeper version of this framework, including a printable evaluation worksheet for use during product audits, the EV SELECT GUIDE is available free to clinicians on the Resources page. References ## Primary sources - Welsh JA, et al. (incl. St-Denis-Bissonnette F) . Minimal information for studies of extracellular vesicles (MISEV2023) . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - Théry C, Witwer KW, Aikawa E, et al. . Minimal information for studies of extracellular vesicles 2018 (MISEV2018) . Journal of Extracellular Vesicles , 2018 . doi.org/ 10.1080/20013078.2018.1535750 - Health Canada . Guidance on cosmetic notification . , 2024 . www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics.html Related reading ## Continue exploring EV Science ### The biomolecular corona, and why isolation method changes what an EV product actually is Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved. For Clinicians ### Extracellular vesicles versus PRP for skin applications PRP and EV preparations are both growth-factor-rich biological inputs that act through cellular signalling. They differ in origin, consistency, delivery, patient experience, and evidence maturity. Treating them as competitors misses the point. For Clinicians ### Post-procedure EV protocols: what we can say, and what is still under evaluation Post-laser, post-microneedling, post-chemical peel: clinics are increasingly asking where EV serums fit. The honest answer requires separating mechanistic plausibility, preclinical signal, and confirmed clinical outcome. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Blog — Aloe barbadensis-derived EVs in skin Source: https://biotherasolutions.com/blog/aloe-derived-evs-skin ============================================================================== Resources / Blog EV Science # Aloe barbadensis-derived extracellular vesicles in dermocosmetic formulation Aloe vera has a 3,000-year cosmetic history. The nanovesicles inside aloe leaf parenchyma are a more recent finding. Their cargo, their stability, and their suitability as a scalable dermocosmetic active deserve separate treatment from the broader plant-EV literature. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Aloe vera (Aloe barbadensis) sits in an unusual position in cosmetic biology. Its use in skincare predates modern dermatology by several thousand years, and the bioactivity of its inner-leaf gel is among the best-documented in botanical medicine. What sat undescribed inside that gel until recently is a population of nanoscale extracellular vesicles released by the parenchymal cells of the aloe leaf. Those vesicles are now characterizable, isolable, and suitable as a scalable dermocosmetic active. Treating aloe-derived EVs as if they were just another plant-EV source misses what makes them practical. Aloe is one of a small number of plant species where the historical cosmetic record, the modern phytochemistry, and the EV biology line up. ## What is in an aloe-derived EV preparation Aloe leaf parenchyma is a hydrated polysaccharide-rich tissue. Cells in this tissue release extracellular vesicles in the size range typical of plant-derived EVs, with particle diameters concentrated in the small-EV range and a population profile measurable by NTA. The cargo profile of these vesicles, characterized through proteomic and biochemical analyses across multiple research groups, includes three categories of bioactive content that are relevant to skin formulation. The first is the antioxidant fraction. Aloe leaves contain phenolic compounds and free-radical-scavenging molecules that are partially encapsulated in the EV population. These compounds are well-characterized antioxidants in cell-based assays and contribute to the biological activity of aloe preparations more broadly. The second is the skin-soothing fraction. Signalling lipids and small bioactive molecules associated in cell-based research with calming and conditioning effects on cultured skin cells are present in the EV population. The cosmetic literature on aloe extract skin-soothing activity has documented these classes of molecules for decades; the EV-encapsulated subset of them is the more recent finding. The third is the skin-renewal fraction. Growth factor-associated proteins and miRNA species studied for their role in supporting skin cell renewal and proliferation in cell-based research are present in the EV cargo. This category aligns with the cross-kingdom EV literature, which has documented preclinical effects of plant-EV cargo on mammalian skin cells across multiple plant sources. ## Why aloe is operationally practical Three practical properties make aloe a defensible source for scalable dermocosmetic EV manufacturing. Biomass scalability. Aloe is one of the most agriculturally tractable plants in cosmetic supply chains. It grows under a wide range of conditions, accepts greenhouse and outdoor cultivation, has predictable harvest cycles, and produces high biomass per unit area. The economics of EV isolation depend on the cost-per-gram of the input biomass; aloe is closer to commodity-economy than to specialty botanical inputs. Regulatory familiarity. Aloe vera as a cosmetic ingredient has decades of regulatory history under Health Canada, the EU Cosmetic Regulation, and FDA cosmetic frameworks. The base ingredient is well-characterized for safety. EV preparations from aloe operate as a more specific, more characterized form of the same source material, with the additional characterization data manufacturers like BioThera apply on top. Consumer recognition. Aloe has 3,000 years of cosmetic and folk-medicine history and is one of the most consumer-recognized active ingredients in skincare globally. For a category, EVs, that is itself unfamiliar to most consumers, sourcing from a familiar species lowers the cognitive load on the product story without requiring marketing to overstate the EV science. ## The honest version of what aloe-derived EVs do It is worth stating clearly what an aloe-derived EV preparation is and is not, in the same vocabulary the broader EV field uses. It is a characterized population of plant-derived nanoscale particles, with a cargo profile dominated by antioxidant, soothing, and skin-renewal-associated molecule classes, suitable for topical cosmetic application as a characterized active. The mechanistic basis for its activity is supported by the cross-kingdom EV literature, by the broader phytochemistry of aloe, and, for a specific product, by that product's own characterization data. It is not a therapeutic agent. It is not a substitute for medical-grade interventions. It is not a cure or treatment for any condition, and credible manufacturers do not present it that way. The framing under Health Canada Cosmetic Regulations is that it is a cosmetic active with documented antioxidant and soothing activity in the EV preparation form, characterized to standards substantially exceeding what the cosmetic category requires. ## Where this fits in the BioThera platform BioThera's first commercial application, the Vesera™ Serum, is built around plant-derived extracellular vesicles. Aloe is one of the medicinal plant sources that fits the operational profile we built the platform to deliver: scalable biomass, characterized cargo, regulatory familiarity, and a consumer-side story that does not have to outpace the science. The platform is designed to be source-flexible at scale; the choice to begin with medicinal plant biomass is a calibration to current evidence and current regulatory pathways, not a permanent constraint. For clinicians: the question to ask of any aloe-derived EV product is the same set of five questions we apply to any EV product. Source specificity, particle concentration, batch CoA, isolation method, cold chain. The history of aloe in cosmetics does not exempt an EV product from those criteria. It is a feature of the source. The characterization is what makes the product. References ## Primary sources - Kim MK, Choi YC, Cho SH, Choi JS, Cho YW. . The antioxidant effect of small extracellular vesicles derived from aloe vera peels for wound healing . Tissue Engineering and Regenerative Medicine , 2021 . doi.org/ 10.1007/s13770-021-00367-8 - Cho SH, Kim MK, et al. . Aloe-derived extracellular vesicles: characterization and dermal delivery applications . International Journal of Molecular Sciences , 2022 . doi.org/ 10.3390/ijms23052787 - Kim J, Li S, Zhang S, Wang J. . Plant-derived exosome-like nanoparticles and their therapeutic activities . Asian Journal of Pharmaceutical Sciences , 2022 . doi.org/ 10.1016/j.ajps.2021.05.006 - Surjushe A, Vasani R, Saple DG. . Aloe vera: a short review . Indian Journal of Dermatology , 2008 . doi.org/ 10.4103/0019-5154.44785 Related reading ## Continue exploring EV Science ### Plant-derived versus mammalian extracellular vesicles, compared honestly Both are bilayer-enclosed nanoscale particles. The differences in safety, scalability, regulatory pathway, and clinical evidence are not minor. They are the reason the two modalities belong in different parts of the EV product map. EV Science ### Cross-kingdom EV signalling: what the evidence supports, and what it does not Plant-derived EVs are taken up by mammalian cells. Their cargo can modulate gene expression in preclinical models. Clinical translation in human skin is where the evidence base is still maturing. Reading the literature requires holding both at once. EV Science ### The biomolecular corona, and why isolation method changes what an EV product actually is Two preparations from the same biomass can carry different protein coronas if they were isolated by different methods. The corona is part of the active ingredient. Most commercial EV products do not disclose how it was preserved. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE ============================================================================== # Blog — Post-procedure EV protocols Source: https://biotherasolutions.com/blog/post-procedure-ev-protocols ============================================================================== Resources / Blog For Clinicians # Post-procedure EV protocols: what we can say, and what is still under evaluation Post-laser, post-microneedling, post-chemical peel: clinics are increasingly asking where EV serums fit. The honest answer requires separating mechanistic plausibility, preclinical signal, and confirmed clinical outcome. FS Frédéric St-Denis-Bissonnette, PhD Founder & CEO, BioThera Solutions Energy-based and resurfacing procedures, fractional and ablative lasers, microneedling, chemical peels, work by inducing controlled, localized damage to the skin and letting the wound-healing cascade do the rest. The clinical interest in EV serums in this context is straightforward: if EV cargo modulates the cellular signalling pathways that the wound-healing cascade depends on, applying EVs immediately post-procedure is a mechanistically plausible adjunct to recovery. Dermatology clinics are increasingly asking where this fits. The honest answer requires separating three layers: mechanistic plausibility, preclinical signal, and confirmed clinical outcome. They are not the same thing, and the gap between them is where most premature claims about EV serums sit. ## The mechanistic case Post-procedure skin is in a temporary state of induced injury. Barrier function is compromised, inflammatory mediators are elevated, fibroblast activity is upregulated, and re-epithelialization, neocollagen synthesis, and matrix remodelling are the dominant biological events of the first 1 to 4 weeks. Many of these processes are modulated, in the broader research literature, by signalling molecules that EV preparations are known to deliver. Antioxidant cargo to attenuate oxidative stress in the recovering tissue. Anti-inflammatory signalling lipids and proteins to limit the duration and intensity of the inflammatory phase. Growth-factor-associated cargo to support the proliferative and remodelling phases. The mechanistic logic is real. It is also not, by itself, sufficient evidence that any given EV serum improves any given post-procedure endpoint in any specific patient population. Mechanism is necessary but not sufficient. ## The preclinical signal The preclinical literature on EV cargo and skin recovery is substantial and growing. Mammalian-derived EV preparations, especially MSC-EV preparations, have shown effects on wound closure, fibroblast proliferation, and inflammation reduction in murine in vivo models and in cell culture systems relevant to skin repair. Plant-derived EV preparations have shown overlapping but distinct functional categories of activity in the same kinds of models, with the cross-kingdom EV literature documenting cargo uptake by mammalian cells and downstream gene expression effects. For BioThera's Vesera™ preparation specifically, our characterization data confirms the presence of antioxidant, soothing, and skin-renewal-associated bioactive cargo classes consistent with the broader plant-EV literature. That is the level at which we make claims about the preparation. We do not extrapolate from the broader literature to outcomes about our specific product. ## The clinical outcome layer Confirmed clinical outcome data, in humans, in controlled post-procedure protocols, at scale, is the layer where the EV field still has most of its work ahead of it. There are early-phase clinical evaluations of EV serums for post-procedure recovery in the published literature, and there is growing dermatologist-led real-world experience. The published evidence base is not yet at the level of mature large-scale randomized data. What this means in practice: a clinician evaluating EV serums for post-procedure protocols today is making a decision in a space where the mechanism is well supported, the preclinical signal is consistent and growing, and the formal clinical endpoint data is earlier than it will be in three to five years. That is a defensible space to operate in for cosmetic, post-procedure, and adjunctive use cases. It is not a defensible space for therapeutic claims about specific endpoints in specific patient populations. ## What we are doing about the evidence gap BioThera's Vesera™ Serum is currently in active dermatologist-led clinical evaluation under Health Canada's cosmetic regulatory framework. The work is designed to generate the kind of structured human-use outcome data that the post-procedure use case specifically benefits from. We are not a clinical trial sponsor in the therapeutic sense; we are a cosmetic manufacturer running a clinical evaluation program at a substantially higher rigour than the cosmetic category requires. The data from that program is what underwrites the claims we are willing to make about the product. The data from broader EV literature is what underwrites the mechanistic and preclinical layer. Keeping those separate is part of how we communicate the science honestly. ## What clinicians can defensibly do today For practices considering integrating an EV serum into post-procedure protocols, three operational principles are worth holding. First, evaluate the specific product by the five-criteria framework: source, particle concentration, Certificate of Analysis, isolation method, cold chain. A characterized EV preparation is the only kind of product the post-procedure case is built on. An uncharacterized "exosome serum" is not a clinical-grade input regardless of mechanism. Second, position the EV serum where the mechanistic case is strongest. Antioxidant and soothing support during early recovery. Adjunctive use alongside a standard post-procedure regimen, not as a replacement for it. Documented patient response in the practice's own records. Third, communicate the evidence position to patients honestly. Mechanism well supported. Preclinical signal consistent. Clinical evidence growing. That is the version of the story that holds up. Anything more aggressive is selling against the field, not with it. The goal is not to oversell EV serums for post-procedure use. It is to give clinicians a framework for using them where the science already supports their use, while being clear about the boundary between today's evidence and tomorrow's. That boundary is where credible EV manufacturers should be operating. References ## Primary sources - Welsh JA, et al. (incl. St-Denis-Bissonnette F) . Minimal information for studies of extracellular vesicles (MISEV2023) . Journal of Extracellular Vesicles , 2024 . doi.org/ 10.1002/jev2.12404 - Park GH, Kwon HH, Seok J, et al. . Effectiveness of modified phototherapy and microneedling for the treatment of melasma in Asians . Lasers in Medical Science , 2020 . doi.org/ 10.1007/s10103-019-02786-5 - Kim YJ, Yoo SM, Park HH, et al. . Extracellular vesicles from human umbilical cord mesenchymal stem cells stimulate cell proliferation and skin regeneration . Stem Cell Research & Therapy , 2017 . doi.org/ 10.1186/s13287-017-0622-2 - Hettich BF, Bader JJ, Leroux JC. . Encapsulation of hydrophilic compounds in small extracellular vesicles: loading capacity and impact on vesicle functions . Advanced Healthcare Materials , 2022 . doi.org/ 10.1002/adhm.202100047 Related reading ## Continue exploring For Clinicians ### Extracellular vesicles versus PRP for skin applications PRP and EV preparations are both growth-factor-rich biological inputs that act through cellular signalling. They differ in origin, consistency, delivery, patient experience, and evidence maturity. Treating them as competitors misses the point. For Clinicians ### How to evaluate an EV or exosome product before stocking it Five criteria: source, particle concentration, Certificate of Analysis, isolation method, cold chain. None are optional. Each one separates a characterized EV preparation from a label that uses the word "exosome" without backing it. EV Science ### Aloe barbadensis-derived extracellular vesicles in dermocosmetic formulation Aloe vera has a 3,000-year cosmetic history. The nanovesicles inside aloe leaf parenchyma are a more recent finding. Their cargo, their stability, and their suitability as a scalable dermocosmetic active deserve separate treatment from the broader plant-EV literature. Discuss the science ## Questions on this topic? Clinicians, researchers, and partners are welcome to go deeper. We treat scientific dialogue as a working part of the platform, not a sales channel. Contact the team EV SELECT GUIDE